# AUTHOR INDEX TO VOLUME 57


Aase H. *See* Sagvolden T
Abelson JL. *See* Fitzgerald KD
Abelson JL, Curtis GC, Sagher O, Albucher RC, Harrigan M, Taylor SF, Martis B, Giordani B. Deep brain stimulation for refractory obsessive-compulsive disorder, 510
Abi-Dargham A. *See* Frankle WG
Abi-Saab WM. *See* D'Souza DC
Adesman A. *See* Ashtari M
Adler LA. *See* Kessler RC
Ahmadpour O. *See* Rapaport MH
Ahn Y-M. *See* Kim Y
Aizenstein HJ. *See* Rosano C
Akil M. *See* Deep-Soboslay A
Albucher RC. *See* Abelson JL
Aleardi M. *See* Spencer T
Alimohamad H, Rajakumar N, Seah Y-H, Rushlow W. Antipsychotics alter the protein expression levels of ß-catenin and GSK-3 in the rat medial prefrontal cortex and striatum, 533
Allen PS. *See* Coupland NJ
Allin MP. *See* Nosarti C
Alves SE. *See* Gundlah C
Amir N, Klumpp H, Elias J, Bedwell JS, Yanasak N, Miller LS. Increased activation of the anterior cingulate cortex during processing of disgust faces in individuals with social phobia, 975
Anand A, Li Y, Wang Y, Wu J, Gao S, Bukhari L, Mathews VP, Kalnin A, Lowe MJ. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study, 1079
Andersen SL. *See* Mague SD
Anderson GM. *See* Tordjman S
Anderson IM. *See* Richell RA
Andreasen NC. *See* Pressler M
Aoki-Suzuki M, Yamada K, Meerabux J, Iwayama-Shigeno Y, Ohba H, Iwamoto K, Takao H, Toyota T, Suto Y, Nakatani N, Dean B, Nishimura S, Seki K, Kato T, Itohara S, Nishikawa T, Yoshikawa T. A family-based association study and gene expression analyses of netrin-G1 and -G2 genes in schizophrenia, 382
Araghi-Niknam M. *See* Fatemi SH
Arango V. *see* Erraji-Benchekroun L; Vinod KY
Arciero G. *See* Bertolino A
Ardekani BA. *See* Ashtari M
Arnsten AFT. *See* Ma C-L
Arnsten AFT, Li B-M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions, 1377
Aron AR, Poldrack RA. The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder, 1285
Arseneault L. *See* Caspi A
Aru GN. *See* Bortolato M
Asbahr FR, Garvey MA, Snider LA, Zanetta DM, Elkis H, Swedo SE. Obsessive-compulsive symptoms among patients with Sydenham chorea, 1073
Ashby ER. *See* Strasser HC
Asherson P. *See* Kuntsi J
Ashtari M, Kumra S, Bhaskar SL, Clarke T, Thaden E, Cervellione KL, Rhinewine J, Kane JM, Adesman A, Milanaik R, Maytal J, Diamond A, Szeszko P, Ardekani BA. Attention-deficit/hyperactivity disorder: a preliminary diffusion tensor imaging study, 448
Ashwin C. *See* Welchew DE
Attia E, Wolk S, Cooper T, Glasofer D, Walsh BT. Plasma tryptophan during weight restoration in patients with anorexia nervosa, 674
Aubry J-M. *See* Karege F
Avila M. *See* Hong LE

Baldini-Rossi N. *See* Haznedar MM
Balkaya M. *See* Winter B
Bar G. *see* Heresco-Levy U
Barci BM. *See* Torrey EF
Barkley R. *See* Kessler RC
Baron-Cohen S. *See* Welchew DE
Barr CS. *See* Newman TK
Barr RG. *See* O'Driscoll GA
Barrot M. *See* Lucas G
Barta PE. *See* Strasser HC
Bartalini S. *See* Rossi S
Bartko JJ. *See* Torrey EF
Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder, 474
Bathalon GP. *See* Lieberman HR
Bation R. *See* Poulet E
Battistini N. *See* Rossi S
Bayerlein K, Hillemacher T, Reulbach U, Mugele B, Sperling W, Kornhuber J, Bleich S. Alcoholism-associated hyperhomocysteinemia and previous withdrawal seizures, 1590
Beck KD. *See* Servatius RJ
Becker T. *See* Hoefgen B
Bediou B. *See* Poulet E
Bedwell JS. *See* Amir N
Bencherif B. *See* Gorelick DA
Ben-Shachar D. *See* Laifenfeld D
Benson BE. *See* Little JT
Berger G. *See* Smesny S
Bergmann A. *See* Brettschneider S
Berkouk K. *See* Welchew DE
Bernardi G. *See* Centonze D; Federici M
Bertolino A, Arciero G, Rubino V, Latorre V, De Candia M, Mazzola V, Blasi G, Caforio G, Hariri A, Kolachana B, Nardini M, Weinberger DR, Scarabino T. Variation of human amygdala response during threatening stimuli as a functionof 5'HTTLPR genotype and personality style, 1517
Bertschy G. *See* Karege F
Best S. *See* Otte C
Beuthien-Baumann B. *See* Holthoff VA
Bhaskar SL. *See* Ashtari M
Biba A. *See* Tsaltas E
Biederman J. *See* Doyle AE; Kessler RC; Smoller JW; Spencer T; Spencer TJ; Valera EM
Biederman J. Attention-deficit/hyperactivity disorder: a selective overview, 1215
Bigelow LB. *See* Deep-Soboslay A
Bihrle S. *See* Yang Y
Binder EB. *See* Pfennig A
Birnbaum D. *See* Swann AC
Blasi G. *See* Bertolino A
Bleich S. *See* Bayerlein K



0006-3223/05/$30.00
doi:10.1016/S0006-3223(05)00639-6

BIOL PSYCHIATRY 2005;57:1611–1625


© 2005 Society of Biological Psychiatry

Blitzer RD, Iyengar R, Landau EM. Postsynaptic signaling networks: cellular cogwheels underlying long-term plasticity, 113
Bluhm RL. *See* Lanius RA
Bockaert J. *See* Lucas G
Bohning DE. *See* Denslow S
Boksman K. *See* Lanius RA
Boland BS. *See* Fonder MA
Bonab AA. *See* Spencer TJ
Bondolfi G. *See* Karege F
Bonne O. *See* Neumeister A
Bortolato M, Aru GN, Frau R, Orrù M, Fà M, Manunta M, Puddu M, Mereu G, Gessa GL. Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats, 1550
Boyd SJ. *See* Gorelick DA
Braff DL. *See* Cadenhead KS
Braff DL, Light GA, Ellwanger J, Sprock J, Swerdlow NR. Female schizophrenia patients have prepulse inhibition deficits, 817
Brain EE. *See* Neumeister A
Braithwaite A. *See* Caspi A
Braley G. *See* D'Souza DC
Brammer MJ. *See* Surguladze S
Brand JE. *See* Shestyuk AY
Brandt PC. *See* Browning JL
Brazo P. *See* Dollfus S
Brennan FX. *See* Pawlyk AC
Bresee CJ. *See* Rapaport MH
Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schultz C, Bürger K, Dodel R, Du Y, Möller H-J, Bergmann A, Hampel H. Decreased serum amyloid b1-42 autoantibody levels in Alzheimer's disease determined by a newly developed immuno-precipitation assay in radiolabeled amyloid ß$_{1-42}$ peptide, 813
Breuer M. *See* van der Stelt HM
Britton JC, Phan KL, Taylor SF, Fig LM, Liberzon I. Corticolimbic blood flow in posttraumatic stress disorder during script-driven imagery, 832
Brody SA, Nakanishi N, Tu S, Lipton SA, Geyer MA. A developmental influence of the N-methyl-D-aspartate receptor NR3A subunit on prepulse inhibition of startle, 1147
Brooks AI. *See* Fatemi SH
Brooks L. *See* Greenwood BN
Brown ES, Stuard G, Liggin JDM, Hukovic N, Frol A, Dhanani N, Khan DA, Jeffress J, Larkin GL, McEwen BS, Rosenblatt R, Mageto Y, Hanczyc M, Cullum CM. Effect of phenytoin on mood and declarative memory during prescription corticosteroid therapy, 543
Browning JL, Patel T, Brandt PC, Young KA, Holcomb LA, Hicks PB. Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions, 617
Bruder GE. *See* Grillon C
Bruder GE, Tenke CE, Warner V, Nomura Y, Grillon C, Hille J, Leite P, Weissman MM. Electroencephalographic measures of regional hemispheric activity in offspring at risk for depressive disorders, 328
Brunelin J. *See* Poulet E
Buchsbaum MS. *See* Haznedar MM
Buckmaster CL. *See* Parker KJ
Bukhari L. *See* Anand A
Bullmore E. *See* Welchew DE
Bundo M. *See* Munakata K
Bürger K. *See* Brettschneider S
Burhans D. *See* Greenwood BN
Burnet PWJ. *See* Eastwood SL
Busch R. *See* Leucht S
Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions, 1273

Cadenhead KS, Light GA, Shafer KM, Braff DL. P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment, 1504
Caesar S. *See* Raybould R
Caforio G. *See* Bertolino A
Calabresi P. *See* Centonze D
Campeau S. *See* Greenwood BN
Cangiano C. *See* Frankle WG
Cannon M. *See* Caspi A
Carlezon WA Jr. *See* Mague SD
Carlezon WA Jr, Mague SD, Parow AM, Stoll AL, Cohen BM, Renshaw PF. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats, 343
Carlezon WA Jr, Rohan ML, Mague SD, Meloni EG, Parsegian A, Cayetano K, Tomasiewicz HC, Rouse ED, Cohen BM, Renshaw PF. Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats, 571
Carper RA, Courchesne E. Localized enlargement of the frontal cortex in earlyh autism, 126
Carroll K. *See* Petrakis IL
Carter CS. *See* Rosano C
Carter P. *See* Volkow ND
Cary M. *See* Furlan PM
Casey BJ. *See* Hare TA
Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction, 1117
Castellanos FX, Sonuga-Barke EJS, Scheres A, Di Martino A, Hyde C, Walters JR. Varieties of attention-deficit/hyperactivity disorder-related intra-individual variability, 1416
Castner SA, Vosler PS, Goldman-Rakic PS. Amphetamine sensitization impairs cognition and reduces dopamine turnover in primate prefrontal cortex, 743
Castrogiovanni P. *See* Rossi S
Catinari S. *see* Heresco-Levy U
Cayetano K. *See* Carlezon WA Jr
Celone K. *See* Kiehl KA
Centonze D, Rossi S, Prosperetti C, Tscherter A, Bernardi G, Maccarrone M, Calabresi P. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease m1583ice
Cervellione KL. *See* Ashtari M
Chadha KR. *See* Hanna GL
Champoux M. *See* Newman TK

Chang L, Cloak C, Patterson K, Grob C, Miller EN, Ernst T. Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response, 967
Charbuy H. *See* Tordjman S
Charles PJ. *See* Habeych ME
Charnay Y. *See* Lucas G
Charney D. *See* Milham MP
Charney DS. *See* Neumeister A; Zarate CA Jr
Chitnis XA. *See* Sumich A
Chouinard V-A. *See* Doyle AE
Christodoulou A. *See* Tsaltas E
Chrysikakou S. *See* Tsaltas E
Cintron CM. *See* Rosso IM
Claes S. *See* León SL
Clark CM. *See* Strome EM
Clark JA. *See* Gundlah C
Clark JA, Pai L-Y, Flick RB, Rohrer SP. Differential hormonal regulation of tryptophan hydroxylase-2 mRNA in the murine dorsal raphe nucleus, 943
Clark L, Kempton MJ, Scarnà A, Grasby PM, Goodwin GM. Sustained attention-deficit confirmed in euthymic bipolar disorder but not in first-degree relatives of bipolar patients or euthymic unipolar depression, 183
Clarke T. *See* Ashtari M
Cleare AJ, Messa C, Rabiner EA, Grasby PM. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635, 239
Cloak C. *See* Chang L
Cloitre M. *See* Protopopescu X
Cochran JL. *See* Rosano C
Cohen BM. *See* Carlezon WA Jr
Colletti P. *See* Yang Y
Compan V. *See* Lucas G
Condy C, Wattiez N, Rivaud-Péchoux S, Gaymard B. Ketamine-induced distractibility: an oculomotor study in monkeys, 366
Conners CK. *See* Kessler RC
Connor DF. *See* Wilens TE
Constantino JN, Todd RD. Intergenerational transmission of subthreshold autistic traits in the general population, 655
Cooper T. *See* Attia E
Cooper TB. *See* D'Souza DC; Milak MS; Vinod KY
Copersino M. *See* Gorelick DA
Costa E. *See* Tremolizzo L
Coupland NJ, Ogilvie CJ, Hegadoren KM, Seres P, Hanstock CC, Allen PS. Decreased prefrontal *myo*-inositol in major depressive disorder, 1526
Courchesne E. *See* Carper RA
Cowen PJ. *See* Hayward G
Craddock N. *See* Raybould R
Craig IW. *See* Caspi A
Cranney J. *See* Ledgerwood L
Crawford TJ, Higham S, Renvoize T, Patel J, Dale M, Suriya A, Tetley S. Inhibitory control of saccadic eye movements and cognitive impairment in Alzheimer's disease, 1052
Croes EA. *See* León SL
Csernansky JG. *See* Selemon LD
Cullum CM. *See* Brown ES
Curtis GC. *See* Abelson JL
Czarkowski KA. *See* Epperson CN

Dale M. *See* Crawford TJ
Dalery J. *See* Poulet E
d'Amato T. *See* Poulet E
Dannals RF. *See* Gorelick DA
Davidson MC. *See* Hare TA
Davis J. *See* Tremolizzo L
Davis M. *See* Jovanovic T; Sánchez MM
Day HEW. *See* Greenwood BN
De Candia M. *See* Bertolino A
De Jesus G. *See* Zarate CA Jr
De Kosky ST. *See* Rosano C
De Rosa E. *See* Sullivan EV
De Sarno P. *See* Roh M-S
Deakin JFW. *See* Richell RA
Dean B. *See* Aoki-Suzuki M; Digney A
Debonnel G. *See* Lucas G
Deep-Soboslay A, Akil M, Martin CE, Bigelow LB, Herman MM, Hyde TM, Kleinman JE. Reliability of psychiatric diagnosis in postmortem research, 96
Delamillieure P. *See* Dollfus S
Deldin PJ. *See* Shestyuk AY
Delrahim KK. *See* Rapaport MH
Denicoff KD. *See* Zarate CA Jr
Denslow S, Lomarev M, George MS, Bohning DE. Cortical and subcortical brain effects of transcranial magnetic stimulation (TMS)-induced movement: an interleaved TMS/functional magnetic resonance imaging study, 752
Densmore M. *See* Lanius RA
Dépatie L. *See* O'Driscoll GA
Depaulo JR. *See* Strasser HC
Deshmukh A. *See* Sullivan EV
Deveney CM. *See* Shestyuk AY
Dhanani N. *See* Brown ES
Di Martino A. *See* Castellanos FX
Di Muro A. *See* Rossi S
Diamond A. *See* Ashtari M
Diamond DM. *See* Sandi C
Dickstein DP. *See* Milham MP
Digney A, Keriakous D, Scarr E, Thomas E, Dean B. Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder, 711
Ding Y-S. *See* Volkow ND
Ditman T. *See* Holt DJ
Dodel R. *See* Brettschneider S
Doersch a. *See* D'Souza DC
Doku VC. *See* Sumich A
Dollfus S, Razafimandimby A, Delamillieure P, Brazo P, Joliot M, Mazoyer B, Tzourio-Mazoyer N. Atypical hemispheric specialization for language in right-handed schizophrenia patients, 1020
Dolnak D. *See* Rapaport MH
Dong E. *See* Tremolizzo L
Doudet DJ. *See* Strome EM
Doueiri M-S. *See* Tremolizzo L
Dougherty DD. *See* Spencer TJ
Dougherty DM. *See* Swann AC
Douglas VI. *See* O'Driscoll GA
Doyle AE. *See* Faraone SV; Nigg JT; Willcutt EG
Doyle AE, Willcutt EG, Seidman LJ, Biederman J, Chouinard V-A, Silva J, Faraone SV. Attention-deficit/hyperactivity disorder endophenotypes, 1324
Doyle R. *See* Spencer T
Drevets WC. *See* Milham MP; Neumeister A
D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal

JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction, 594
Du Y. *See* Brettschneider S
Dudas MM. *See* Fonder MA
Dudman JT. *See* MacDonald ML
Duncan EJ. *See* Jovanovic T
Dunn RT. *See* Little JT

Eastwood SL, Burnet PWJ, Harrison PJ. Decreased hippocampal expression of the susceptibility gene PPP3CC and other calcineurin subunits in schizophrenia, 702
Eaton ME. *See* MacDonald ML
Ebstein R. *see* Heresco-Levy U
Eckermann A. *See* Hoefgen B
Eesley CE. *See* Keefe RSE
Elias J. *See* Amir N
Elkis H. *See* Asbahr FR
Ellwanger J. *See* Braff DL
Endres CJ. *See* Gorelick DA
Endres M. *See* Winter B
Engelien W. *See* Protopopescu X
Eom T-Y. *See* Roh M-S
Epperson CN, O'Malley S, Czarkowski KA, Gueorguieva R, Jatlow P, Sanacora G, Rothman DL, Krystal JH, Mason GF. Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy, 44
Epstein J. *See* Protopopescu X
Ermilov M. *see* Heresco-Levy U
Ernst G. *See* Pfennig A
Ernst M. *See* Milham MP
Ernst T. *See* Chang L
Erraji-Benchekroun L, Underwood MD, Arango V, Galfalvy H, Pavlidis P, Smyrniotopoulos P, Mann JJ, Sibille E. Molecular aging in human prefrontal cortex is sselective and continuous throughout adult life, 549
Evans DL. *See* Furlan PM

Fà M. *See* Bortolato M
Fabrazzo M. *See* Monteleone P
Fagerness JA. *See* Smoller JW
Falco CM. *See* Lieberman HR
Faldrowicz A. *See* Sumich A
Fan J-B, Zhang C-S, Gu N-F, Li X-W, Sun W-W, Wang H-Y, Feng G-Y, St. Clair D, He L. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis, 139
Fannon DG. *See* Sumich A
Faraone S. *See* Spencer T
Faraone SV. *See* Doyle AE; Kessler RC; Smoller JW; Spencer TJ; Valera EM; Willcutt EG
Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder, 1313
Farde L. *See* Jucaite A
Farshbaf M. *See* Sagvolden T
Fatemi SH, Snow AV, Stary JM, Araghi-Niknam M, Reutiman TJ, Lee S, Brooks AI, Pearce DA. Reeling signaling is impaired in autism, 777
Federici M, Geracitano R, Bernardi G, Mercuri NB. Actions of methylphenidate on dopaminergic neurons of the ventral midbrain, 361
Feng G-Y. *See* Fan J-B
Fernell E. *See* Jucaite A
Ferrier IN. *See* Gallagher P
Fiallos A. *See* Jovanovic T
Fig LM. *See* Britton JC
Fischer DJ. *See* Hanna GL
Fischer-Schultz C. *See* Brettschneider S
Fischman AJ. *See* Madras BK; Spencer TJ
Fischman AJ, Madras BK. The neurobiology of attention-deficit/hyperactivity disorder, 1374
Fitzgerald DA. *See* Phan KL
Fitzgerald KD, Welsh RC, Gehring WJ, Abelson JL, Himle JA, Liberzon I, Taylor SF. Error-related hyperactivity of the anterior cingulate cortex in obsessive-compulsive disorder, 287
Fleshner M. *See* Greenwood BN
Fletcher PJ. *See* Tenn CC
Flick RB. *See* Clark JA
Foley TE. *See* Greenwood BN
Fonder MA, Sacco KA, Termine A, Boland BS, Seyal AA, Dudas MM, Vessicchio JC, George TP. Smoking cue reactivity in schizophrenia: effects of a nicotine receptor antagonist, 802
Forgeard L. *See* Poulet E
Forselius-Bielen K. *See* D'Souza DC
Forssberg H. *See* Jucaite A
Fowler JS. *See* Volkow ND
Frangou S. *See* Nosarti C
Frankle WG, Narendran R, Huang Y, Hwang D-R, Lombardo I, Cangiano C, Gil R, Laruelle M, Abi-Dargham A. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB, 1510
Frau R. *See* Bortolato M
Fregni F. *See* Rumi DO
Friedman MJ, Wang S, Jalowiec JE, McHugo GJ, McDonagh-Coyle A. Thyroid hormone alterations among women with posttraumatic stress disorder due to childhood sexual abuse, 1186
Frol A. *See* Brown ES
Frost JJ. *See* Gorelick DA
Frost SJ. *See* Jacobsen LK
Fuchs B. *See* Pfennig A
Furlan PM, Have TT, Cary M, Zemel B, Wehrli F, Katz IR, Gette DR, Evans DL. The role of stress-induced cortisol in the relationship between depression and decreased bone mineral density, 911

Galfalvy H. *see* Erraji-Benchekroun L
Gallagher P, Watson S, Smith MS, Ferrier IN, Young AH. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia, 155
Galloway GP. *See* Salo R
Gao S. *See* Anand A
García-Bueno B, Madrigal JLM, Lizasoain I, Moro MA, Lorenzo P, Leza JC. Peroxisome proliferative-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats, 885
Garvey MA. *See* Asbahr FR
Gati JS. *See* Lanius RA
Gatley JS. *See* Volkow ND
Gattaz WF. *See* Rumi DO
Gaymard B. *See* Condy C
Gaymard BM. *See* Ploner CJ

Gehring WJ. *See* Fitzgerald KD
George MS. *See* Denslow S
George TP. *See* Fonder MA
Geracitano R. *See* Federici M
Gervasoni N. *See* Karege F
Gessa GL. *See* Bortolato M
Gette DR. *See* Furlan PM
Geyer MA. *See* Brody SA; Risbrough VB
Giampietro V. *See* Surguladze S
Giannou H. *See* Tsaltas E
Gietz A. *See* Winter B
Gil R. *See* Frankle WG
Gilbert DL, Sallee FR, Zhang J, Lipps TD, Wassermann EM. Transcranial magnetic stimulation-evoked cortical inhibition: a consistent marker of attention-deficit hyperactivity disorder scores in Tourette syndrome, 1597
Giordani B. *See* Abelson JL
Giordani C. *See* Monteleone P
Glasofer D. *See* Attia E
Glover GH. *See* Hare TA
Goff DC. *See* Holt DJ
Goldman MB. *See* Mitchell CP
Goldman-Rakic PS. *See* Castner SA; Selemon LD
Goldsmith M. *See* Koren D
Goldstein M. *See* Protopopescu X
Goodwin GM. *See* Clark L; Hayward G
Goracci A. *See* Rossi S
Goralnick JJ. *See* Faraone SV
Gordon-Smith K. *See* Raybould R
Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino M, Endres CJ, Dannals RF, Frost JJ. Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving, 1573
Gorman J. *See* Protopopescu X
Graessle M. *See* Newman TK
Grant P. *See* Snider LA
Grantz H. *See* Leckman JF
Grasby PM. *See* Clark L; Cleare AJ
Grayson DR. *See* Mitchell CP; Tremolizzo L
Green EK. *See* Raybould R
Greenhill LL. *See* Kessler RC
Greenwood BN, Foley TE, Day HEW, Burhans D, Brooks L, Campeau S, Fleshner M. Wheel running alters serotonin (5-HT) transporter, 5-HT1A, 5-HT1B, and alpha1b-adrenergic receptor mRNA in the rat raphe nuclei, 559
Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents, 261
Grillon C. *See* Bruder GE
Grillon C, Warner V, Hille J, Merikangas KR, Bruder GE, Tenke CE, Nomura Y, Leite P, Weissman MM. Families at high and low risk for depression: a three-generation startle study, 953
Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge-eating disorder: a randomized, double-blind, placebo-controlled trial, 1193
Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison, 301
Grob C. *See* Chang L
Gross M. *See* Hoefgen B
Gruber SA. *See* Hooley JM
Gu N-F. *See* Fan J-B
Gueorguieva R. *See* D'Souza DC; Epperson CN
Guidotti A. *See* Tremolizzo L
Gundlah C, Alves SE, Clark JA, Pai L-Y, Schaeffer JM, Rohrer SP. Estrogen receptor-ß regulates tryptophan hydroxylase-1 expression in the murine midbrain raphe, 938

Habeych ME, Charles PJ, Sclabassi RJ, Kirisci L, Tarter RE. Direct and mediated associations between P300 amplitude in childhood and substance use disorders outcome in young adulthood, 76
Haight BR. *See* Wilens TE
Halldin C. *See* Jucaite A
Hamann J. *See* Leucht S
Hampel H. *See* Brettschneider S
Hampton KD. *See* Wilens TE
Hanczyc M. *See* Brown ES
Hanna GL, Fischer DJ, Chadha KR, Himle JA, Van Etten M. Familial and sporadic subtypes of early-onset obsessive-compulsive disorder, 895
Hanna SE. *See* Sakic B
Hanstock CC. *See* Coupland NJ
Hare TA, Tottenham N, Davidson MC, Glover GH, Casey BJ. Contributions of amygdala and striatal activity in emotion regulation, 624
Hariri A. *See* Bertolino A
Harmer CJ. *See* Hayward G
Harrigan M. *See* Abelson JL
Harrington H. *See* Caspi A
Harris MSH. *See* Reilly JL
Harrison PJ. *See* Eastwood SL
Hashimoto K. *See* Yamada K
Hashimoto R, Okada T, Kato T, Kosuga A, Tatsumi M, Kamijima K, Kunugi H. The breakpoint cluster region gene on chromosome 22q11 is associated with bipolar disorder, 1097
Hashimoto T. *See* Hill JJ
Have TT. *See* Furlan PM
Haynes VF. *See* Sandi C
Hayward G, Goodwin GM, Cowen PJ, Harmer CJ. Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms, 517
Haznedar MM, Roversi F, Pallanti S, Baldini-Rossi N, Schnur DB, LiCalzi EM, Tang C, Hof PR, Hollander E, Buchsbaum MS. Fronto-thalamo-striatal gray and white matter volumes and anistropy of their connections in bipolar spectrum illnesses, 733
He L. *See* Fan J-B
Heckers S. *See* Holt DJ
Hegadoren KM. *See* Coupland NJ
Heidmann V. *See* Hoefgen B
Henn-Haase C. *See* Otte C
Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia, 577
Herholz K. *See* Holthoff VA
Herman MM. *See* Deep-Soboslay A
Heron J. *See* Raybould R
Herzig K. *See* Spencer T
Heun R. *See* Hoefgen B
Hicks PB. *See* Browning JL
Higham S. *See* Crawford TJ

Higley JD. *See* Newman TK
Hill JJ, Kolluri N, Hashimoto T, Wu Q, Sampson AR. Monteggia LM, Lewis DA. Analysis of pyramidal neuron morphology in an inducible knockout of brain-derived neurotrophic factor, 932
Hille J. *See* Bruder GE; Grillon C
Hillemacher T. *See* Bayerlein K
Hiller JB. *See* Hooley JM
Himle JA. *See* Fitzgerald KD; Hanna GL
Hirshfeld-Becker D. *See* Smoller JW
Ho B-C. *See* Pressler M
Hochrein A. *See* Hoenig K
Hoefgen B, Schulze TG, Ohlraun S, von Widdern O, Höfels S, Gross M, Heidmann V, Kovalenko S, Eckermann A, Kölsch H, Metten M, Zobel A, Becker T, Nöthen MM, Propping P, Heun R, Maier W, Rietschel M. The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder, 247
Hoenig K, Hochrein A, Quednow BB, Maier W, Wagner M. Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder, 1153
Hof PR. *See* Haznedar MM
Höfels S. *See* Hoefgen B
Holahan A-L V. *See* O'Driscoll GA
Holcomb H. *See* Hong LE
Holcomb LA. *See* Browning JL
Hollander E. *See* Haznedar MM
Holmgren MA. *See* Faraone SV
Holsboer F. *See* Pfennig A
Holt DJ, Weiss AP, Rauch SL, Wright CI, Zalesak M, Goff DC, Ditman T, Welsh RC, Heckers S. Sustained activation of the hippocampus in response to fearful faces in schizophrenia, 1011
Holthoff VA, Beuthien-Baumann B, Kalbe E, Lüdecke S, Lenz O, Zündorf G, Spirling S, Schierz K, Winiecki P, Sorbi S, Herholz K. Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression, 412
Honeycutt NA. *See* Strasser HC
Hong LE, Tagamets M, Avila M, Wonodi K, Holcomb H, Thaker GK. Specific motion processing pathway deficit duringe eye tracking in schizophrenia: a performance-matched functional magnetic resonance imaging study, 726
Hooley JM, Gruber SA, Scott LA, Hiller JB, Yurgelun-Todd DA. Activation in dorsolateral prefrontal cortex in response to maternal criticism and praise in recovered depressed and healthy control participants, 809
Hopkins RO. *See* Strasser HC
Horrigan JP. *See* Wilens TE
Hörtnagl H. *See* Winter B
Huang Y. *See* Frankle WG
Hudziak JJ. *See* Wilens TE
Hukovic N. *See* Brown ES
Hungund BL. *See* Vinod KY
Hwang D-R. *See* Frankle WG
Hyde C. *See* Castellanos FX
Hyde S. *See* Raybould R
Hyde TM. *See* Deep-Soboslay A

Irle E, Lange C, Sachsse U. Reduced size and abnormal asymmetry of parietal cortex in women with borderline personality disorder, 173
Ising M. *See* Pfennig A
Itohara S. *See* Aoki-Suzuki M
Itokawa M. *See* Yamada K
Iwamoto K. *See* Aoki-Suzuki M; Munakata K
Iwayama-Shigeno Y. *See* Aoki-Suzuki M; Yamada K
Iyengar R. *See* Blitzer RD
Iyo M. *See* Yamada K

Jacobsen LK, Krystal JH, Mencl WE, Westerveld M, Frost SJ, Pugh KR. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers, 56
Jaeger S. *See* Kessler RC
Jahn AL. *See* Pizzagalli DA
Jajar AA. *See* Swann AC
Jalowiec JE. *See* Friedman MJ
Jatlow P. *See* Epperson CN
Javitt DC. *see* Heresco-Levy U
Jayne M. *See* Volkow ND
Jeffress J. *See* Brown ES
Jha SK. *See* Pawlyk AC
Johansen EB. *See* Sagvolden T
Jolicoeur C. *See* O'Driscoll GA
Joliot M. *See* Dollfus S
Jones I. *See* Raybould R
Jones L. *See* Raybould R
Jope RS. *See* Roh M-S
Jovanovic T, Keyes M, Fiallos A, Myers KM, Davis M, Duncan EJ. Fear potentiation and fear inhibition in a human fear-potentiated startle paradigm, 1559
Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity, 229
Juckel G. *See* Winter B
Juhnn Y-S. *See* Kim Y
Jurkovich G. *See* Zatzick DF
Justus KR. *See* Parker KJ

Kagan J. *See* Smoller JW
Kalbe E. *See* Holthoff VA
Kalnin A. *See* Anand A
Kamijima K. *See* Hashimoto R
Kanba S. *See* Nakao T
Kane JM. *See* Ashtari M; Leucht S
Kang U-G. *See* Kim Y
Kaplan P. *See* Nickel MK
Kapur S. *See* Tenn CC; Turrone P
Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry J-M, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity, 1068
Karry R. *See* Laifenfeld D
Kassir SA. *See* Vinod KY
Katchanov J. *See* Winter B
Kato T. *See* Aoki-Suzuki M; Hashimoto R; Munakata K
Katsovich L. *See* Leckman JF
Katz IR. *See* Furlan PM
Kawamoto M. *See* Nakao T
Kawikova I. *See* Leckman JF
Keedwell P. *See* Surguladze S

Keefe RSE, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia, 688
Kempton MJ. *See* Clark L
Keriakous D. *See* Digney A
Kern N. *See* Pfennig A
Keshavan MS. *See* Reilly JL
Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV, Greenhill LL, Jaeger S, Secnik K, Spencer T, Ustun TB, Zaslavsky AM. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the National Comorbidity Survey replication, 1442
Ketter TA. *See* Little JT
Keyes M. *See* Jovanovic T
Khan DA. *See* Brown ES
Kiehl KA, Stevens MC, Celone K, Kurtz M, Krystal JH. Abnormal hemodynamics in schizophrenia during an auditory oddball task, 1029
Kile S. *See* Salo R
Kim Y, Seo M-S, Kang U-G, Yoon SG, Ahn Y-M, Kim YS, Juhnn Y-S. Activation of Cdk2-pRB-E2F1 cell cycle pathway by repeated electroconvulsive shock in the rat frontal cortex, 107
Kim YK. *See* Gorelick DA
Kim YS. *See* Kim Y
Kimbrell TA. *See* Little JT
Kimura Y. *See* Yoshino A
Kinder D. *See* Smesny S
King RA. *See* Leckman JF
Kipp K. A developmental perspective on the measurement of cognitive deficits in attention-deficit/hyperactivity disorder, 1256
Kirisci L. *See* Habeych ME
Kirov G. *See* Raybould R
Kissling W. *See* Leucht S
Klein E. *See* Laifenfeld D
Klein EM. *See* Koren D
Kleinman JE. *See* Deep-Soboslay A
Kleinschmidt A. *See* Sterzer P
Klumpp H. *See* Amir N
Knable MB. *See* Torrey EF
Kolachana B. *See* Bertolino A
Kolehmainen AI. *See* Riikonen RS
Kolluri N. *See* Hill JJ
Kölsch H. *See* Hoefgen B
Könöen M. *See* Riikonen RS
Konradi C. *See* MacDonald ML
Kontis D. *See* Tsaltas E
Koren D, Poyurovsky M, Seidman LJ, Goldsmith M, Wenger S, Klein EM. The neuropsychological basis of competence to consent in first-episode schizophrenia: a pilot metacognitive study, 609
Kornhuber J. *See* Bayerlein K
Kosten TA. *See* Zhang XY
Kosten TR. *See* Li C-S Ray
Kosuga A. *See* Hashimoto R
Kovalenko S. *See* Hoefgen B
Kramer FM. *See* Lieberman HR
Krawczyk J. *See* Nickel MK
Krebs A. *See* Sterzer P
Krishnan KRP. Through the looking glass: risk perception, 1477
Krönig H. *See* Leckman JF
Krystal JH. *See* D'Souza DC; Epperson CN; Jacobsen LK; Kiehl KA
Kuczenski R, Segal DS. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse, 1391
Kudoh A. *See* Nakao T
Kuikka JT. *See* Riikonen RS
Kuller LH. *See* Rosano C
Kumar AM. *See* McBurnett K
Kumar M. *See* McBurnett K
Kumpulainen KI. *See* Riikonen RS
Kumra S. *See* Ashtari M
Kuntsi J, Rijsdijk F, Ronald A, Asherson P, Plomin R. Genetic influences on the stability of attention-deficit/hyperactivity disorder symptoms from early to middle childhood, 647
Kunugi H. *See* Hashimoto R
Kunzel HE. *See* Pfennig A
Kurian E. *See* Strasser HC
Kurtz M. *See* Kiehl KA

LaCasse L. *See* Yang Y
Lahey BB. *See* McBurnett K
Lahmann C. *See* Nickel MK
Laifenfeld D, Karry R, Klein E, Ben-Shachar D. Alterations in cell adhesion molecule L1 and functionally related genes in major depression: a postmortem study, 716
Laird NM. *See* Smoller JW
Landau EM. *See* Blitzer RD
Lange C. *See* Irle E
Langley K. *See* Turic D
Lanius RA, Williamson PC, Bluhm RL, Densmore M, Boksman K, Neufeld RWJ, Gati JS, Menon RS. Functional connectivity of dissociative responses in posttraumatic stress disorder: a functional magnetic resonance imaging investigation, 873
Larkin GL. *See* Brown ES
Laruelle M. *See* Frankle WG
Lasch J. *See* Smesny S
Latorre V. *See* Bertolino A
Learned-Coughlin S. *See* Volkow ND
Leckman JF, Katsovich L, Kawikova I, Lin H, Zhang H, Krönig H, Morshed S, Parveen S, Grantz H, Lombroso PJ, King RA. Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome, 667
Ledgerwood L, Richardson R, Cranney J. D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction, 841
LeDoux J. *See* Protopopescu X
Lee S. *See* Fatemi SH
Leibenluft E. *See* Milham MP
Leiberich PK. *See* Nickel MK
Leite P. *See* Bruder GE; Grillon C
Lencz T. *See* Yang Y
Lenz O. *See* Holthoff VA
Leon AC. *See* Nelson JC
León SL, Croes EA, Sayed-Tabatabaei FA, Claes S, Van Broeckhoven C, van Duijn CM. The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: a meta-analysis, 999
Lesch K-P. *See* Newman TK
Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypotheis of antipsychotic drug action: a hypothesis tested, confirmed and extended, 1543
Levinson C. *See* Petrakis IL

Lewis DA. *See* Hill JJ
Leza JC. *See* García-Bueno B
Li B-M. *See* Arnsten AFT; Ma C-L
Li C-S Ray, Kosten TR, Sinha R. Sex differences in brain activation during stress imagery in abstinent cocaine users: a functional magnetic resonance imaging study, 487
Li X-W. *See* Fan J-B
Li Y. *See* Anand A
Liberzon I. *See* Britton JC; Fitzgerald KD
LiCalzi EM. *See* Haznedar MM
Lichtenberg P. *see* Heresco-Levy U
Lieberman HR, Bathalon GP, Falco CM, Kramer FM, Morgan CA III, Niro P. Severe decrements in cognition function and mood induced by sleep loss, heat, dehydration, and undernutrition during simulated combat, 422
Liggin JDM. *See* Brown ES
Light GA. *See* Braff DL; Cadenhead KS
Lilyestrom J. *See* Strasser HC
Lin H. *See* Leckman JF
Lipps TD. *See* Gilbert DL
Lipton SA. *See* Brody SA
Little JT, Ketter TA, Kimbrell TA, Dunn RT, Benson BE, Willis MW, Luckenbaugh DA, Post RM. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression, 220
Lizasoain I. *See* García-Bueno B
Loeber R. *See* McBurnett K
Loew TH. *See* Nickel MK
Logan J. *See* Volkow ND
Lomarev M. *See* Denslow S
Lombardo I. *See* Frankle WG
Lombroso PJ. *See* Leckman JF
Lopez OL. *See* Rosano C
Lopez-Fernandez MA. *See* Sandi C
Lorenzo P. *See* García-Bueno B
Lougee L. *See* Snider LA
Lowe MJ. *See* Anand A
Lu PH. *See* Bartzokis G
Lucas G, Compan V, Charnay Y, Neve RL, Nestler EJ, Bockaert J, Barrot M, Debonnel G. Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists, 918
Luckenbaugh DA. *See* Little JT; Neumeister A; Zarate CA Jr
Lüdecke S. *See* Holthoff VA
Lyon CK. *See* Sánchez MM
Lyons DM. *See* Parker KJ

Ma C-L, Arnsten AFT, Li B-M. Locomotor hyperactivity induced by blockade of prefrontal cortical α2-adrenoceptors in monkeys, 192
Maccarrone M. *See* Centonze D
MacDonald ML, Eaton ME, Dudman JT, Konradi C. Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the fronal cortex of the rat, 1041
MacGregor S. *See* Raybould R
Maddux RE. *See* Rapaport MH
Madonick S. *See* D'Souza DC
Madras BK. *See* Fischman AJ; Spencer TJ
Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder, 1397
Madrigal JLM. *See* García-Bueno B
Mageto Y. *See* Brown ES
Magué SD. *See* Carlezon WA Jr
Magué SD, Andersen SL, Carlezon WA Jr. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats, 120
Maier W. *See* Hoefgen B; Hoenig K
Maillis A. *See* Tsaltas E
Maj M. *See* Monteleone P
Majer M. *See* Pfennig A
Makris N. *See* Seidman LJ
Manji HK. *See* Zarate CA Jr
Mann JJ. *see* Erraji-Benchekroun L; Milak MS; Vinod KY
Mansur C. *See* Rumi DO
Mantani T, Okamoto Y, Shirao N, Okada G, Yamawaki S. Reduced activation of posterior cingulate cortex during imagery in subjects with high degrees of alexithymia: a functional magnetic resonance imaging study, 982
Mantovani A. *See* Rossi S
Manunta M. *See* Bortolato M
Marcolin MA. *See* Rumi DO
Marmar CR. *See* Otte C
Martiadis V. *See* Monteleone P
Martin CE. *See* Deep-Soboslay A
Martinez V, Parikh V, Sarter M. Sensitized attentional performance and Fos-like immunoreactive cholinergic neurons in the basal forebrain of amphetamine-pretreated rats, 1138
Martins S. *See* Rohde LA
Martis B. *See* Abelson JL
Masheb RM. *See* Grilo CM
Mason GF. *See* Epperson CN
Mathews VP. *See* Anand A
Maytal J. *See* Ashtari M
Mazoyer B. *See* Dollfus S
Mazzola V. *See* Bertolino A
McBurnett K, Raine A, Stouthamer-Loeber M, Loeber R, Kumar AM, Kumar M, Lahey BB. Mood and hormone responses to psychological challenge in adolescent males with conduct problems, 1109
McClay J. *See* Caspi A
McDonagh-Coyle A. *See* Friedman MJ
McEwen BS. *See* Brown ES
McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics, 1367
McHugo GJ. *See* Friedman MJ
Meador-Woodruff JH. *See* Torrey EF
Meerabux J. *See* Aoki-Suzuki M
Meloni EG. *See* Carlezon WA Jr
Mencl WE. *See* Jacobsen LK
Menon RS. *See* Lanius RA
Mercuri NB. *See* Federici M
Mereu G. *See* Bortolato M
Merikangas KR. *See* Grillon C
Messa C. *See* Cleare AJ
Metten M. *See* Hoefgen B
Metzler T. *See* Otte C
Mick E. *See* Spencer T
Milak MS, Ogden RT, Vinocur DN, Van Heertum RL, Cooper TB, Mann JJ, Parsey RV. Effects of tryptophan depletion on the binding of [11C]-DASB to the serotonin transporter in baboons: response to acute serotonin deficiency, 102
Milanaik R. *See* Ashtari M
Milham MP, Nugent AC, Drevets WC, Dickstein DP, Leibenluft E, Ernst M, Charney D, Pine DS. Selective reduction in

amygdala volume in pediatric anxiety disorders: a voxel-based morphometry investigation, 961
Miller EN. *See* Chang L
Miller GM. *See* Madras BK
Miller LS. *See* Amir N
Millward JM. *See* Sakic B
Minabe Y. *See* Yamada K
Mintz J. *See* Bartzokis G
Mitchell CP, Grayson DR, Goldman MB. Neonatal lesions of the ventral hippocampal formation alter GABA-A receptor subunit mRNA expression in adult rat frontal lobe, 49
Miyahara S. *See* Nierenberg AA
Modell JG. *See* Wilens TE
Moeller FG. *See* Swann AC
Moffitt TE. *See* Caspi A
Moghaddam B. *See* Stefani MR
Moldow RL. *See* Servatius RJ
Möller H-J. *See* Brettschneider S
Monteggia LM. *See* Hill JJ
Monteleone P, Martiadis V, Rigamonti AE, Fabrazzo M, Giordani C, Muller EE, Maj M. Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa, 926
Moore C. *See* Salo R
Moore GJ. *See* Phan KL
Moreno RA. *See* Rumi DO
Morgan CA III. *See* Lieberman HR
Morgenthaler NG. *See* Brettschneider S
Mori N. *See* Yamada K
Moro MA. *See* García-Bueno B
Morrison AR. *See* Pawlyk AC
Morshed S. *See* Leckman JF
Moskvina V. *See* Turic D
Mueller-Oehring EM. *See* Schulte T
Mugele B. *See* Bayerlein K
Mühlbacher M. *See* Nickel MK
Muller EE. *See* Monteleone P
Munakata K, Iwamoto K, Bundo M, Kato T. Mitochondrial DNA 3243A >G mutation and increased expression of *LARS2* gene in the brains of patients with bipolar disorder and schizophrenia, 525
Murray R. *See* Caspi A
Murray RM. *See* Nosarti C
Myczkowski ML. *See* Rumi DO
Myers KM. *See* Jovanovic T

Nabeyama M. *See* Nakao T
Nakagawa A. *See* Nakao T
Nakamura K. *See* Yamada K
Nakanishi N. *See* Brody SA
Nakao T, Nakagawa A, Yoshiura T, Nakatani E, Nabeyama M, Yoshizato C, Kudoh A, Tada K, Yoshioka K, Kawamoto M, Togao O, Kanba S. Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study, 901
Nakatani E. *See* Nakao T
Nakatani N. *See* Aoki-Suzuki M
Nardini M. *See* Bertolino A
Narendran R. *See* Frankle WG
Nathan PJ. *See* Phan KL
Natsuaki Y. *See* Salo R
Nebel MB. *See* Selemon LD
Nelson JC, Portera L, Leon AC. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?, 1535
Nelson R. *See* Gorelick DA
Nemeroff CB. *See* Sánchez MM
Nestler EJ. *See* Lucas G
Neufeld RWJ. *See* Lanius RA
Neumeister A, Wood S, Bonne O, Nugent AC, Luckenbaugh DA, Young T, Brain EE, Charney DS, Drevets WC. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects, 935
Neve RL. *See* Lucas G
Newman AB. *See* Rosano C
Newman TK, Syagailo YV, Barr CS, Wendland JR, Champoux M, Graessle M, Suomi SJ, Higley JD, Lesch K-P. Monoamine oxidase A gene promoter variation and rearing experience influences aggressive behavior in rhesus monkeys, 167
Neylan TC. *See* Otte C
Nich C. *See* Petrakis IL
Nickel C. *See* Nickel MK
Nickel MK, Nickel C, Kaplan P, Lahmann C, Mühlbacher M, Tritt K, Krawczyk J, Leiberich PK, Rother WK, Loew TH. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study, 495
Nierenberg AA, Miyahara S, Spencer T, Wisniewski SR, Otto MW, Simon N, Pollack MH, Ostacher MJ, Yan L, Siegel R, Sachs GS. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants, 1467
Nigg JT. *See* Willcutt EG
Nigg JT. Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade, 1424
Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJS. Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes?, 1224
Nikolov I. *See* Raybould R
Niro P. *See* Lieberman HR
Nishikawa T. *See* Aoki-Suzuki M
Nishimura S. *See* Aoki-Suzuki M
Noble PM. *See* Sánchez MM
Nobrega JN. *See* Turrone P
Nokelainen P. *See* Riikonen RS
Nomura S. *See* Yoshino A
Nomura Y. *See* Bruder GE; Grillon C
Nopoulos P. *See* Pressler M
Nordahl TE. *See* Salo R
Norton N. *See* Turic D
Nosarti C, Allin MP, Frangou S, Rifkin L, Murray RM. Hyperactivity in adolescents born very preterm is associated with decreased caudate volume, 661
Nöthen MM. *See* Hoefgen B
Nugent AC. *See* Milham MP; Neumeister A

O'Ceallaigh S. *See* Sumich A
O'Donnell P. *See* Peters YM
O'Donovan MC. *See* Raybould R; Turic D
O'Driscoll GA, Dépatie L, Holahan A-L V, Savion-Lemieux T, Barr RG, Jolicoeur C, Douglas VI. Executive functions and methylphenidate response in subtypes of attention-deficit/hyperactivity disorder, 1452
Ogden RT. *See* Milak MS

Ogilvie CJ. *See* Coupland NJ
Ohba H. *See* Aoki-Suzuki M; Yamada K
Ohlraun S. *See* Hoefgen B
Ohnishi T. *See* Yamada K
Okada G. *See* Mantani T
Okada T. *See* Hashimoto R
Okamoto Y. *See* Mantani T
Okuno A. *See* Yamada K
Olivier B. *See* van der Stelt HM
O'Malley S. *See* Epperson CN
Orrù M. *See* Bortolato M
O'Shea JP. *See* Pizzagalli DA
Ostacher MJ. *See* Nierenberg AA
Otte C, Neylan TC, Pole N, Metzler T, Best S, Henn-Haase C, Yehuda R, Marmar CR. Association between childhood trauma and catecholamine response to psychological stress in polic academy recruits, 27
Otto MW. *See* Nierenberg AA
Owen MJ. *See* Raybould R; Turic D

Pai L-Y. *See* Clark JA; Gundlah C
Pallanti S. *See* Haznedar MM
Pallidi S. *See* Tsaltas E
Pan H. *See* Protopopescu X
Pappas N. *See* Volkow ND
Parikh V. *See* Martinez V
Park CR. *See* Sandi C
Parker KJ, Buckmaster CL, Justus KR, Schatzberg AF, Lyons DM. Mild early life stress enhances prefrontal-dependent response inhibition in monkeys, 848
Parow AM. *See* Carlezon WA Jr
Parsegian A. *See* Carlezon WA Jr
Parsey RV. *See* Milak MS
Parveen S. *See* Leckman JF
Passero S. *See* Rossi S
Patel J. *See* Crawford TJ
Patel T. *See* Browning JL
Patterson K. *See* Chang L
Pauls DL. The genetics of attention-deficit/hyperactivity disorder, 1310
Pavlidis P. *see* Erraji-Benchekroun L
Pawlyk AC, Jha SK, Brennan FX, Morrison AR, Ross RJ. A rodent model of sleep disturbances in posttraumatic stress disorder: the role of context after fear conditioning, 268
Pearce DA. *See* Fatemi SH
Pearlson GD. *See* Strasser HC
Pennington BF. *See* Willcutt EG
Pennington BF. Toward a new neuropsychological model of attention-deficit/hyperactivity disorder: subtypes and multiple deficits, 1221
Perlis RH. *See* Faraone SV
Peters YM, O'Donnell P. Social isolation rearing affects prefrontal cortical response to ventral tegmental area stimulation, 1205
Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders, 1128
Pfefferbaum A. *See* Schulte T; Sullivan EV
Pfennig A, Kunzel HE, Kern N, Ising M, Majer M, Fuchs B, Ernst G, Holsboer F, Binder EB. Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression, 336
Phan KL. *See* Britton JC
Phan KL, Fitzgerald DA, Nathan PJ, Moore GJ, Uhde TW, Tancer ME. Neural substrates for voluntary suppression of negative affect: a functional magnetic resonance imaging study, 210
Phillips ML. *See* Surguladze S
Pichard N. *See* Tordjman S
Pierrot-Deseilligny C. *See* Ploner CJ
Pine DS. *See* Milham MP
Pinna G. *See* Tremolizzo L
Pitman RK. *See* Zatzick DF
Pizzagalli DA, Jahn AL, O'Shea JP. Toward an objective characterization of an anhedonic phenotype: a signal-detection approach, 319
Pliszka SR. The neuropsychopharmacology of attention-deficit/hyperactivity disorder, 1385
Plomin R. *See* Kuntsi J
Ploner CJ, Gaymard BM, Rivaud-Péchoux S, Pierrot-Deseilligny C. The prefrontal substrate of reflexive saccade inhibition in humans, 1159
Plotsky PM. *See* Sánchez MM
Poe MP. *See* Keefe RSE
Polanczyk G. *See* Rohde LA
Poldack RA. *See* Valera EM
Poldrack RA. *See* Aron AR
Pole N. *See* Otte C
Poling J. *See* Petrakis IL
Pollack MH. *See* Nierenberg AA
Portera L. *See* Nelson JC
Post RM. *See* Little JT
Potash JB. *See* Strasser HC
Poulet E, Brunelin J, Bediou B, Bation R, Forgeard L, Dalery J, d'Amato T, Saoud M. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia, 188
Poulton R. *See* Caspi A
Poustka F. *See* Sterzer P
Poyurovsky M. *See* Koren D
Pressler M, Nopoulos P, Ho B-C, Andreasen NC. Insular cortex abnormalities in schizophrenia: relationship to symptoms and typical neuroleptic exposure, 394
Prince J. *See* Spencer T
Propping P. *See* Hoefgen B
Prosperetti C. *See* Centonze D
Protopopescu X, Pan H, Tuescher O, Cloitre M, Goldstein M, Engelien W, Epstein J, Yang Y, Gorman J, LeDoux J, Silbersweig D, Stern E. Differential time courses and specificity of amygdala activity in posttraumatic stress disorder subjects and normal control subjects, 464
Puddu M. *See* Bortolato M
Pugh KR. *See* Jacobsen LK
Pulver AE. *See* Strasser HC

Quednow BB. *See* Hoenig K
Quiroz JA. *See* Zarate CA Jr

Rabavilas A. *See* Tsaltas E
Rabiner EA. *See* Cleare AJ
Racette S. *See* Smoller JW
Raine A. *See* McBurnett K; Yang Y
Rajakumar N. *See* Alimohamad H
Rakic P. *See* Selemon LD

Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia, 1594
Rauch SL. *See* Holt DJ
Rauch SL. Neuroimaging and attention-deficit/hyperactivity disorder in the 21st century: what to consider and how to proceed, 1261
Raybould R, Green EK, MacGregor S, Gordon-Smith K, Heron J, Hyde S, Caesar S, Nikolov I, Williams N, Jones L, O'Donovan MC, Owen MJ, Jones I, Kirov G, Craddock N. Bipolar disorder and polymorphisms in the dysbindin gene *(DTNBP1),* 696
Razafimandimby A. *See* Dollfus S
Reilly JL, Harris MSH, Keshavan MS, Sweeney JA. Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia, 145
Remington G. *See* Turrone P
Renshaw PF. *See* Carlezon WA Jr; Rosso IM
Renvoize T. *See* Crawford TJ
Reulbach U. *See* Bayerlein K
Reutiman TJ. *See* Fatemi SH
Rhinewine J. *See* Ashtari M
Richard NE. *See* Wilens TE
Richardson R. *See* Ledgerwood L
Richell RA, Deakin JFW, Anderson IM. Effect of acute tryptophan depletion on the response to controllable and uncontrollable noise stress, 295
Rietschel M. *See* Hoefgen B
Rifkin L. *See* Nosarti C
Rigamonti AE. *See* Monteleone P
Rigonatti SP. *See* Rumi DO
Riikonen RS, Nokelainen P, Valkonen K, Kolehmainen AI, Kumpulainen KI, Könöen M, Vanninen R-LS, Kuikka JT. Deep serotonergic and dopaminergic structures in fetal alcoholic syndrome: a study with nor-β-CIT-single-photon emission computed tomography and magnetic resonance volumetry, 1565
Rijsdijk F. *See* Kuntsi J
Risbrough VB, Geyer MA. Anxiogenic treatments do not increase fear-potentiated startle in mice, 33
Rivara F. *See* Zatzick DF
Rivaud-Péchoux S. *See* Condy C; Ploner CJ
Robinson TE. *See* Samaha A-N
Rodriguez-Menendez V. *See* Tremolizzo L
Roh M-S, Eom T-Y, Zmijewska AA, De Sarno P, Roth KA, Jope RS. Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine, 278
Rohan ML. *See* Carlezon WA Jr
Rohde LA, Szobot C, Polanczyk G, Schmitz M, Martins S, Tramontina S. Attention-deficit hyperactivity disorder in a diverse culture: do research and clinical findings support the notion of a cultural construct for the disorder?, 1436
Rohrer SP. *See* Clark JA; Gundlah C
Ronald A. *See* Kuntsi J
Rosa MA. *See* Rumi DO
Rosa MO. *See* Rumi DO
Rosano C, Aizenstein HJ, Cochran JL, Saxton JA, De Kosky ST, Newman AB, Kuller LH, Lopez OL, Carter CS. Event-related functional magnetic resonance imaging investigation of executive control in very old impairments with mild cognitive impairment, 761
Rosburg T. *See* Smesny S
Rosenbaum JF. *See* Smoller JW
Rosenblatt R. *See* Brown ES
Rosenbloom MJ. *See* Schulte T; Sullivan EV
Rosenthal NE. *See* Wilens TE
Ross RJ. *See* Pawlyk AC
Rossi S. *See* Centonze D
Rossi S, Bartalini S, Ulivelli M, Mantovani A, Di Muro A, Goracci A, Castrogiovanni P, Battistini N, Passero S. Hypofunctioning of sensory gating mechanisms in patients with obsessive-compulsve disorder, 16
Rosso IM, Cintron CM, Steingard RJ, Renshaw PF, Young AD, Yurgelun-Todd DA. Amygdala and hippocampus volumes in pediatric major depression, 21
Roth KA. *See* Roh M-S
Roth TL, Sullivan RM. Memory of early maltreatment: neonatal behavioral and neural correlates of maternal maltreatment within the context of classical conditioning, 823
Rother WK. *See* Nickel MK
Rothman GL. *See* Epperson CN
Rounsaville B. *See* Petrakis IL
Rouse ED. *See* Carlezon WA Jr
Roversi F. *See* Haznedar MM
Roy-Byrne P. *See* Zatzick DF
Rubino V. *See* Bertolino A
Rumi DO, Gattaz WF, Rigonatti SP, Rosa MA, Fregni F, Rosa MO, Mansur C, Myczkowski ML, Moreno RA, Marcolin MA. Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study, 162
Rushlow W. *See* Alimohamad H
Russell VA. *See* Sagvolden T
Russo J. *See* Zatzick DF

Sacco KA. *See* Fonder MA
Sachs GS. *See* Nierenberg AA
Sachsse U. *See* Irle E
Sagher O. *See* Abelson JL
Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder, 1239
Sakic B, Hanna SE, Millward JM. Behavioral heterogeneity in an animal model of neuropsychiatric lupus, 679
Salameh G. *See* Servatius RJ
Salant SL. *See* Grilo CM
Sallee FR. *See* Gilbert DL
Salo R, Nordahl TE, Moore C, Waters C, Natsuaki Y, Galloway GP, Kile S, Sullivan EV. A dissociation in attentional control: evidence from methamphetamine dependence, 310
Salvador R. *See* Welchew DE
Samaha A-N, Wendy Yau W-Y, Yang P, Robinson TE. Rapid delivery of nicotine promotes behavioral sensitization and alters its neurobiological impact, 351
Sampson AR. *See* Hill JJ
Sanacora G. *See* Epperson CN
Sánchez MM, Noble PM, Lyon CK, Plotsky PM, Davis M, Nemeroff CB, Winslow JT. Alterations in diurnal cortisol rhythm and acoustic startle response in nonhuman primates with adverse rearing, 373
Sandi C, Woodson JC, Haynes VF, Park CR, Touyarot K, Lopez-Fernandez MA, Venero C, Diamond DM. Acute stress-induced impairment of spatial memory is associated

with decreased expression of neural cell adhesion molecule in the hippocampus and prefrontal cortex, 856
Saoud M. *See* Poulet E
Sarter M. *See* Martinez V
Sauer H. *See* Smesny S
Saunders CS. *See* Bartzokis G
Savion-Lemieux T. *See* O'Driscoll GA
Saxton JA. *See* Rosano C
Sayed-Tabatabaei FA. *See* León SL
Scarabino T. *See* Bertolino A
Scarnà A. *See* Clark L
Scarr E. *See* Digney A
Scatton B. *See* Griebel G
Schaeffer JM. *See* Gundlah C
Schatzberg AF. *See* Parker KJ
Scheres A. *See* Castellanos FX
Schierz K. *See* Holthoff VA
Schlyer D. *See* Volkow ND
Schmitz M. *See* Rohde LA
Schnur DB. *See* Haznedar MM
Schretlen DJ. *See* Strasser HC
Schueller M. *See* Volkow ND
Schulte T, Mueller-Oehring EM, Rosenbloom MJ, Pfefferbaum A, Sullivan EV. Differential effect of HIV infection and alcoholism on conflict processing, attentional allocation, and perceptual load: evidence from a Stroop Match-to-Sample task, 67
Schulze TG. *See* Hoefgen B
Schwald M. *See* Karege F
Schweizer B. *See* Strasser HC
Sclabassi RJ. *See* Habeych ME
Scott LA. *See* Hooley JM
Seah Y-H. *See* Alimohamad H
Secnik K. *See* Kessler RC
Segal DS. *See* Kuczenski R
Seidman LJ. *See* Bush G; Doyle AE; Koren D; Valera EM
Seidman LJ, Valera EM, Makris N. Structural brain imaging of attention-deficit/hyperactivity disorder, 1263
Seki K. *See* Aoki-Suzuki M
Selemon LD, Wang L, Nebel MB, Csernansky JG, Goldman-Rakic PS, Rakic P. Direct and indirect effects of fetal irradiation on cortical gray and white matter volume in the macaque, 83
Self DW. Molecular and genetic approaches for behavioral analysis of protein function, 1479
Seo M-S. *See* Kim Y
Seres P. *See* Coupland NJ
Sergeant JA. Modeling attention-deficit/hyperactivity disorder: a critical appraisal of the cognitive–energetic model, 1248
Servatius RJ, Beck KD, Moldow RL, Salameh G, Tumminello TP, Short KR. A stress-induced anxious state in male rats: corticotropin-releasing hormone induces persistent changes in associative learning and startle reactivity, 865
Seyal AA. *See* Fonder MA
Shafer KM. *See* Cadenhead KS
Sharma T. *See* Sumich A
Shaywitz BA. *See* Shaywitz SE
Shaywitz SE, Shaywitz BA. Dyslexia (specific reading disability), 1301
Shea C. *See* Volkow ND
Shestyuk AY, Deldin PJ, Brand JE, Deveney CM. Reduced sustained brain activity during processing of positive emotional stimuli in major depression, 1089
Shimizu E. *See* Yamada K
Shirao N. *See* Mantani T
Short KR. *See* Servatius RJ
Sibille E. *see* Erraji-Benchekroun L
Siegel R. *See* Nierenberg AA
Silbersweig D. *See* Protopopescu X
Silva J. *See* Doyle AE
Simon N. *See* Nierenberg AA
Singh JB. *See* Zarate CA Jr
Sinha R. *See* Li C-S Ray
Sklar P. *See* Faraone SV
Sklar P. Principles of haplotype mapping and potential applications to attention-deficit/hyperactivity disorder, 1357
Sklar PB. *See* Smoller JW
Slattery M. *See* Snider LA
Slaugenhaupt SA. *See* Smoller JW
Smesny S, Kinder D, Willhardt I, Rosburg T, Lasch J, Berger G, Sauer H. Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia, 399
Smith MS. *See* Gallagher P
Smoller JW. *See* Faraone SV
Smoller JW, Yamaki LH, Fagerness JA, Biederman J, Racette S, Laird NM, Kagan J, Snidman N, Faraone SV, Hirshfeld-Becker D, Tsuang MT, Slaugenhaupt SA, Rosenbaum JF, Sklar PB. The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder, 1485
Smyrniotopoulos P. *see* Erraji-Benchekroun L
Snider LA. *See* Asbahr FR
Snider LA, Lougee L, Slattery M, Grant P, Swedo SE. Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders, 788
Snidman N. *See* Smoller JW
Snow AV. *See* Fatemi SH
Sohr R. *See* Winter B
Sonuga-Barke EJS. *See* Castellanos FX; Nigg JT
Sonuga-Barke EJS. Casual models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways, 1231
Sorbi S. *See* Holthoff VA
Spencer T. *See* Kessler RC; Nierenberg AA
Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S. A large, double-blind randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder, 456
Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougherty DD, Bonab AA, Fischman AJ. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter, 1293
Sperling W. *See* Bayerlein K
Spirling S. *See* Holthoff VA
Sprock J. *See* Braff DL
St. Clair D. *See* Fan J-B
Stadler C. *See* Sterzer P
Stary JM. *See* Fatemi SH
Stefani MR, Moghaddam B. Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia, 433
Steingard RJ. *See* Rosso IM
Stemmelin J. *See* Griebel G
Stern E. *See* Protopopescu X

Sterzer P, Stadler C, Krebs A, Kleinschmidt A, Poustka F. Abnormal neural responses to emotional visual stimuli in adolescents with conduct disorder, 7
Stevens MC. *See* Kiehl KA
Stoll AL. *See* Carlezon WA Jr
Stouthamer-Loeber M. *See* McBurnett K
Strasser HC, Lilyestrom J, Ashby ER, Honeycutt NA, Schretlen DJ, Pulver AE, Hopkins RO, Depaulo JR, Potash JB, Schweizer B, Yates KO, Kurian E, Barta PE, Pearlson GD. Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects: a pilot study, 633
Strome EM, Clark CM, Zis AP, Doudet DJ. Electroconvulsive shock decreases binding to 5-HT2 receptors in nonhuman primates: an in vivo positron emission tomography study with [18F]setoperone, 1004
Stuard G. *See* Brown ES
Suckling J. *See* Welchew DE
Sullivan EV. *See* Salo R; Schulte T
Sullivan EV, Deshmukh A, De Rosa E, Rosenbloom MJ, Pfefferbaum A. Striatal and forebrain nucleic volumes: contribution to motor function and working memory deficits in alcoholism, 768
Sullivan RM. *See* Roth TL
Sumich A, Chitnis XA, Fannon DG, O'Ceallaigh S, Doku VC, Faldrowicz A, Sharma T. Unreality symptoms and volumetric measures of Heschl's gyrus and planum temporal in first-episode psychosis, 947
Sun W-W. *See* Fan J-B
Suomi SJ. *See* Newman TK
Surguladze S, Brammer MJ, Keedwell P, Giampietro V, Young AW, Travis MJ, Williams SCR, Phillips ML. A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder, 201
Suriya A. *See* Crawford TJ
Surman C. *See* Spencer T
Suto Y. *See* Aoki-Suzuki M
Swann AC, Birnbaum D, Jajar AA, Dougherty DM, Moeller FG. Acute yohimbine increases laboratory-measured impulsivity in normal subjects, 1209
Swedo SE. *See* Asbahr FR; Snider LA
Sweeney JA. *See* Reilly JL
Swerdlow NR. *See* Braff DL
Syagailo YV. *See* Newman TK
Szezsko P. *See* Ashtari M
Szobot C. *See* Rohde LA

Tada K. *See* Nakao T
Tagamets M. *See* Hong LE
Takahashi Y. *See* Yoshino A
Takao H. *See* Aoki-Suzuki M; Yamada K
Tancer ME. *See* Phan KL
Tang C. *See* Haznedar MM
Tarter RE. *See* Habeych ME
Tatsumi M. *See* Hashimoto R
Taylor A. *See* Caspi A
Taylor SF. *See* Abelson JL; Britton JC; Fitzgerald KD
Teipel SK. *See* Brettschneider S
Tenke CE. *See* Bruder GE; Grillon C
Tenn CC, Fletcher PJ, Kapur S. A putative animal model of the "prodromal" state of schizophrenia, 586
Termine A. *See* Fonder MA
Tetley S. *See* Crawford TJ
Thaden E. *See* Ashtari M
Thaker GK. *See* Hong LE
Thapar A. *See* Turic D
Thomas E. *See* Digney A
Todd RD. *See* Constantino JN
Togao O. *See* Nakao T
Tomasiewicz HC. *See* Carlezon WA Jr
Tordjman S, Anderson GM, Pichard N, Charbuy H, Touitou Y. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder, 134
Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains, 252
Tottenham N. *See* Hare TA
Touitou Y. *See* Tordjman S
Touyarot K. *See* Sandi C
Toyoshima M. *See* Yamada K
Toyota T. *See* Aoki-Suzuki M; Yamada K
Tramontina S. *See* Rohde LA
Travis MJ. *See* Surguladze S
Tremolizzo L, Doueiri M-S, Dong E, Grayson DR, Davis J, Pinna G, Tueting P, Rodriguez-Menendez V, Costa E, Guidotti A. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice, 500
Tritt K. *See* Nickel MK
Tsaltas E, Kontis D, Chrysikakou S, Giannou H, Biba A, Pallidi S, Christodoulou A, Maillis A, Rabavilas A. Reinforced spatial alteration as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology, 1176
Tscherter A. *See* Centonze D
Tsuang MT. *See* Smoller JW
Tu S. *See* Brody SA
Tuescher O. *See* Protopopescu X
Tueting P. *See* Tremolizzo L
Tumminello TP. *See* Servatius RJ
Turic D, Langley K, Williams H, Norton N, Williams NM, Moskvina V, Van den Bree MB, Owen MJ, Thapar A, O'Donovan MC. A family based study implicates solute carrier family 1-member 3 (SLC1A3) gene in attention-deficit/hyperactivity disorder, 1461
Turner J. *See* Bartzokis G
Turrone P, Remington G, Kapur S, Nobrega JN. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats, 406
Tzourio-Mazoyer N. *See* Dollfus S

Uhde TW. *See* Phan KL
Ulivelli M. *See* Rossi S
Underwood MD. *see* Erraji-Benchekroun L
Ustun TB. *See* Kessler RC

Valera EM. *See* Bush G; Seidman LJ
Valera EM, Faraone SV, Biederman J, Poldack RA, Seidman LJ. Functional neuroanatomy of working memory in adults with attention-deficit/hyperactivity disorder, 439
Valkonen K. *See* Riikonen RS
Van Broeckhoven C. *See* León SL
Van den Bree MB. *See* Turic D

van der Stelt HM, Breuer M, Olivier B, Westenberg HGM. Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study, 1061
van Duijn CM. *See* León SL
Van Etten M. *See* Hanna GL
Van Heertum RL. *See* Milak MS
Vanninen R-LS. *See* Riikonen RS
Vass A. *see* Heresco-Levy U
Venero C. *See* Sandi C
Vessicchio JC. *See* Fonder MA
Viktorov I. *See* Winter B
Vinocur DN. *See* Milak MS
Vinod KY, Arango V, Xie S, Kassir SA, Mann JJ, Cooper TB, Hungund BL. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims, 480
Volkow ND, Wang G-J, Fowler JS, Ding Y-S. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder, 1410
Volkow ND, Wang G-J, Fowler JS, Learned-Coughlin S, Yang J, Logan J, Schlyer D, Gatley JS, Wong C, Zhu W, Pappas N, Schueller M, Jayne M, Carter P, Warner D, Ding Y-S, Shea C, Xu Y. The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects, 640
von Widdern O. *See* Hoefgen B
Vosler PS. *See* Castner SA

Wagner M. *See* Hoenig K
Waldman ID. Statistical approaches to complex phenotypes: evaluating neuropsychological endophenotypes for attention-deficit/hyperactivity disorder, 1347
Walsh BT. *See* Attia E
Walters JR. *See* Castellanos FX
Wang G-J. *See* Volkow ND
Wang H-Y. *See* Fan J-B
Wang L. *See* Selemon LD
Wang S. *See* Friedman MJ
Wang Y. *See* Anand A
Warner D. *See* Volkow ND
Warner V. *See* Bruder GE; Grillon C
Wassermann EM. *See* Gilbert DL
Waters C. *See* Salo R
Watson S. *See* Gallagher P
Wattiez N. *See* Condy C
Webster MJ. *See* Torrey EF
Wehrli F. *See* Furlan PM
Weinberger DR. *See* Bertolino A
Weiss AP. *See* Holt DJ
Weissman MM. *See* Bruder GE; Grillon C
Welchew DE, Ashwin C, Berkouk K, Salvador R, Suckling J, Baron-Cohen S, Bullmore E. Functional disconnectivity of the medial temporal lobe in Asperger's syndrome, 991
Welsch RC. *See* Holt DJ
Welsh RC. *See* Fitzgerald KD
Wendland JR. *See* Newman TK
Wendy Yau W-Y. *See* Samaha A-N
Wenger S. *See* Koren D
Westernberg HGM. *See* van der Stelt HM
Westerveld M. *See* Jacobsen LK
Wilens T. *See* Spencer T
Wilens TE, Haight BR, Horrigan JP, Hudziak JJ, Rosenthal NE, Connor DF, Hampton KD, Richard NE, Modell JG. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized placebo-controlled study, 793
Willcutt EG. *See* Doyle AE; Nigg JT
Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review, 1336
Willhardt I. *See* Smesny S
Williams B. *See* Caspi A
Williams H. *See* Turic D
Williams N. *See* Raybould R
Williams NM. *See* Turic D
Williams SCR. *See* Surguladze S
Williamson PC. *See* Lanius RA
Willis MW. *See* Little JT
Wilson GT. *See* Grilo CM
Winiecki P. *See* Holthoff VA
Winslow JT. *See* Sánchez MM
Winter B, Juckel G, Viktorov I, Katchanov J, Gietz A, Sohr R, Balkaya M, Hörtnagl H, Endres M. Anxious and hyperactive phenotype following brief ischemic episodes in mice, 1166
Wisniewski SR. *See* Nierenberg AA
Wolk S. *See* Attia E
Wong C. *See* Volkow ND
Wonodi K. *See* Hong LE
Wood S. *See* Neumeister A
Woodson JC. *See* Sandi C
Wright CI. *See* Holt DJ
Wu J. *See* Anand A
Wu Q. *See* Hill JJ

Xie S. *See* Vinod KY
Xu Y. *See* Volkow ND

Yamada K. *See* Aoki-Suzuki M
Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M, Okuno A, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu E, Itokawa M, Mori N, Iyo M, Yoshikawa T. Identification of multiple serine racemase *(SRR)* mRNA isoforms and genetic analyses of *SRR* and *DAO* in schizophrenia and D-serine levels, 1493
Yamaki LH. *See* Smoller JW
Yamawaki S. *See* Mantani T
Yan L. *See* Nierenberg AA
Yanasak N. *See* Amir N
Yang J. *See* Volkow ND
Yang P. *See* Samaha A-N
Yang Y. *See* Protopopescu X
Yang Y, Raine A, Lencz T, Bihrle S, LaCasse L, Colletti P. Volume reduction in prefrontal gray matter in unsuccessful criminal psychopaths, 1109
Yates KO. *See* Strasser HC
Yehuda R. *See* Otte C
Yoon SG. *See* Kim Y
Yoshida T. *See* Yoshino A
Yoshikawa T. *See* Aoki-Suzuki M; Yamada K
Yoshino A, Kimura Y, Yoshida T, Takahashi Y, Nomura S. Relationships between temperament dimensions in personality and unconscious emotional responses, 1
Yoshioka K. *See* Nakao T
Yoshiura T. *See* Nakao T
Yoshizato C. *See* Nakao T

Young AD. *See* Rosso IM
Young AH. *See* Gallagher P
Young AW. *See* Surguladze S
Young KA. *See* Browning JL
Young T. *See* Neumeister A
Yurgelun-Todd DA. *See* Hooley JM; Rosso IM

Zalesak M. *See* Holt DJ
Zanetta DM. *See* Asbahr FR
Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression, 430
Zaslavsky AM. *See* Kessler RC
Zatzick DF, Russo J, Pitman RK, Rivara F, Jurkovich G, Roy-Byrne P. Reevaluating the association between emergency department heart rate and the development of posttraumatic stress disorder: a public health approach, 91
Zemel B. *See* Furlan PM
Zhang C-S. *See* Fan J-B
Zhang H. *See* Leckman JF
Zhang J. *See* Gilbert DL
Zhang XY, Kosten TA. Prazosin, an α-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking, 1202
Zhu W. *See* Volkow ND
Zis AP. *See* Strome EM
Zmijewska AA. *See* Roh M-S
Zobel A. *See* Hoefgen B
Zündorf G. *See* Holthoff VA

# SUBJECT INDEX TO VOLUME 57


Acoustic startle
  anxiety disorders and, 953
  corticotropin-releasing hormone effects on, 85
  in monkeys, 373
  prepulse inhibition of
    impaired, in obsessive-compulsive disorder, 1153
    kappa opioid receptor activation disruption of, 1550
    N-methyl-D-aspartate receptor NR3A subunit effects on, 1147
α2-Adrenergic receptors
  prefrontal cortex, locomotor hyperactivity induced blockade of, 192
Adolescents
  attention-deficit/hyperactivity disorder in, 229
  autistic, 6-sulphatoxymelatonin nocturnal excretion in, 134
  with conduct disorder
    description of, 7
    mood and hormone responses to psychological challenge in, 1109
  with depression, 1477
  preterm-birth, hyperactivity associated with caudate volume decreases, 661
  smoking and smoking abstinence in, 56
Affect
  negative, 210
  voluntary suppression of, 210
Aggression
  antisocial behavior and, 7
  in borderline personality disorder, topiramate for, 495
  monoamine oxidase A gene and, 167
  topiramate for, 495
Aging
  prefrontal cortex affected by, 549
Alcoholic suicide victims
  prefrontal cortex of
    CB1 receptor-mediated G-protein signaling in, 480
    endocannabinoids in, 480
Alcoholism
  attentional allocation affected by, 67
  conflict processing affected by, 67
  disulfiram for, 1128
  forebrain nuclei volumes in, 768
  HIV and, 67
  hyperhomocysteinemia associated with, 1590
  naltrexone for, 1128
  perceptual load affected by, 67
  psychiatric disorders comorbid with, 1128
  striatal volumes in, 768
  withdrawal seizures from, 1590
  working memory deficits in, 768
Alexithymia
  posterior cingulate cortex and, 982
Alpha1b-adrenergic receptor, 559
Alzheimer's disease
  amyloid $\beta_{1-42}$ autoantibody levels in, 813
  apathy in, 412
  cognitive impairment in, 1052
  depression in, 412
  regional cerebral metabolism in, 412
  saccadic eye movements in, 1052
Amitriptyline
  depression treated with, 162
  transcranial magnetic stimulation effects on, 162
Amphetamine sensitization
  attentional performance sensitization and, 1138
  cognition affected by, 743
  prefrontal cortex dopamine turnover affected by, 743
Amygdala
  emotion regulation and, 624
  in posttraumatic stress disorder, 464
  threatening stimuli effects on, 1517
  volume of
    in pediatric anxiety, 961
    in pediatric major depression, 21
    selective reduction in, 961
Amyloid $\beta_{1-42}$ autoantibodies
  in Alzheimer's disease, 813
Anhedonia
  in depression, 319
Animal models
  of obsessive-compulsive disorder, 1176
  of schizophrenia, 586
Anorexia nervosa
  plasma tryptophan during weight restoration in, 674
Anterior cingulate
  error-related hyperactivity of, in obsessive-compulsive disorder, 287
Anterior cingulate cortex
  in social phobia-related processing of disgust faces, 975
Antidepressants
  cranial stimulation effects as, 571
  low-field magnetic stimulation effects as, 571
  omega-3 fatty acids effects as, 343
  psychosocial context of response to, 314 (letter)
  radafaxine, 640
  uridine effects as, 343
Antipsychotics
  actions of, 1543
  β-catenin levels affected by, 533
  clozapine's actions as, 617
  early-onset hypothesis of, 1543
  GSK-3 levels affected by, 533
  presynaptic protein mRNA levels elevated by, in frontal cortex of rat, 1041
Antisocial behavior
  aggression and, 7
  stress hormones and, 10109
Anxiety
  brief ischemic episodes and, 1166
  pediatric, 961
  startle reactivity in, 953
  stress-induced, 865
Apathy
  in Alzheimer's disease, 412
Apolipoprotein E
  in bipolar disorder, 711
  in schizophrenia, 711
Asperger's syndrome
  medial temporal lobe functional disconnectivity in, 991
Associative learning
  corticotropin-releasing hormone effects on, 85
Attentional allocation, 67



0006-3223/05/$30.00
doi:10.1016/S0006-3223(05)00642-6

BIOL PSYCHIATRY 2005;57:1626–1634


© 2005 Society of Biological Psychiatry

Attentional control
methamphetamine effects on, 310
Attentional performance
amphetamine effects on, 1138
Attention-deficit/hyperactivity disorder
adult persistence of, 1442
bipolar disorder and, 1467
brain imaging of, 1263
bupropion XL for, 793
causal heterogeneity in, 1224
causal models of, 1231
characteristics of, 1215
cognitive deficits in, 439, 1256
cognitive=energetic model of, 1248
comorbidities, 1467
cultural construct of, 1436
diffusion tensor imaging study of, 448
dopamine transporters in, 229, 1293, 1397
endophenotypes of, 1324, 1347
executive functions in, 1224, 1231, 1336, 1377, 1452
functional neuroimaging of, 1273
genetics of, 647, 1215, 1285, 1310, 1313
haplotype mapping of, 1357
intra-individual variability of, 1416
meta-analysis of, 1336
modeling of, 1248
molecular genetics of, 1313
multiple developmental pathways in, 1231
neurobiology of, 1374
neuroimaging of, 1261, 1273
neuropsychological model of, 1221, 1424
neuropsychopharmacology of, 1385
neuroreceptor imaging in, 1293
overview of, 1215
patterns and predictors of, 1442
pharmacogenomics of, 1367
prevalence of, 1215
response inhibition in, 1285
rodent models of, 1239
single photon emission computed tomography of, 1273
solute carrier family 1-member 3 gene in, 1461
structural brain imaging of, 1263
subtypes of, 1221, 1224, 1452
symptoms of, 647
Tourette's syndrome and, 1597
treatment of
description of, 1215
methylphenidate, 1410, 1452, 1477
stimulants, 1391
varieties of, 1416
working memory in, 439
Auditory hallucinations in schizophrenia
transcranial magnetic stimulation reduction of, 188
Autism
frontal cortex localized enlargement in, 126
intergenerational transmission of traits associated with, 655
melatonin production in, 134
Reelin signaling impairments in, 777
6-sulphatoxymelatonin nocturnally excreted in children and adolescents with, 134
Autoantibodies
amyloid $\beta_{1\text{-}42}$, in Alzheimer's disease, 813
Azithromycin
streptococcal infection prophylaxis using, 788

β-Catenin
antipsychotics' effect on protein expression levels of, 533
Behavioral inhibition
in children, 1485
corticotropin-releasing hormone and, 1485
Binge eating disorder
cognitive behavioral therapy for
description of, 301
orlistat and, 1193
fluoxetine for, 301
Bipolar depression
riluzole and lithium for, 430
Bipolar disorder
apolipoprotein E in, 711
attention-deficit in, 183
attention-deficit/hyperactivity disorder and, 1467
breakpoint cluster region gene on chromosome 22q11 in, 1097
*DTNBP1* polymorphisms and, 696
dysbindin polymorphisms and, 696
euthymic, 183
fronto-thalamo-strial gray volumes in, 733
*LARS2* gene expression in, 525
mitochondrial DNA 3243A >G mutation in, 525
neurochemical markers for, 252
nonpsychotic, 633
psychotic, 633
white matter volume in, 733
Bone mineral density
depression and, 911
Borderline personality disorder
description of, 495
hippocampal size in, 173
parietal cortex in women with, 173
topiramate for aggression in, 495
Brain-derived neurotrophic factor
in depression, 1068
platelet reactivity and, 1068
pyramidal neuron morphology in an inducible knockout of, 932
Breakpoint cluster region on chromosome 22q11
in bipolar disorder, 1097
Brief ischemic episodes
anxious phenotype after, 1166
hyperactive phenotype after, 1166
Brodmann area 46, 1159
Bulimia nervosa
ghrelin responses to, 926
peptide YY responses to, 926
Bupropion
regional cerebral metabolism and, 220
Bupropion XL
attention-deficit/hyperactivity disorder treated with, 793

Calcineurin
in schizophrenia, 702
Calcium-independent phospholipase A2
in schizophrenia, 399
Cannabinoid(s)
psychosis and, 594
in schizophrenia, 594

Cannabinoid CB1 receptor antagonist
emotional reactivity in rodents affected by, 261
in prefrontal cortex of alcoholic suicide victims, 480
Cannabinoid receptor stimulation, 1583
Cannabis
catechol-O-methyltransferase gene polymorphism effects on, 1117
psychosis and, 1117
Catecholamines
childhood trauma and, 27
prefrontal cortical functions affected by, 1377
Catechol-O-methyltransferase gene
adolescent-onset cannabis effects on adult psychosis moderated by, 1117
Val/Met polymorphism, schizophrenia and, 139
[11C]-DASB
positron emission tomography study using, 1510
tryptophan depletion on binding of, to serotonin transporter, 102
Cdk2-pRB-E2F1 cell cycle pathway
electroconvulsive shock effects on, 107
Celecoxib, for schizophrenia, 1594
Cell adhesion molecule L1
in major depression, 716
Cerebral metabolism, regional
in depression, 220
Children
autistic, 6-sulphatoxymelatonin nocturnal excretion in, 134
behavioral inhibition in, 1485
major depression in
amygdala volumes in, 21
hippocampus volumes in, 21
panic disorder in, 1485
sexual abuse, posttraumatic stress disorder caused by, 1186
trauma
catecholamine response and, 27
stress in, 27
Chromosome 22q11
breakpoint cluster region gene on, in bipolar disorder, 1097
Chronic fatigue syndrome
5-HT1A receptor binding in, 239
Clozapine
antipsychotic actions of, 617
mitogen-activated protein kinase signal transduction pathway effects on, 617
Cocaine
craving of, 487, 1573
methylphenidate effects on potentiation of, 120
mu-opioid receptors in users of, 1573
norepinephrine and, 1202
prazosin effects on, 1202
stress-induced craving for, 487
Cognition. *See also* Mild cognitive impairment
Alzheimer's disease-related impairment, 1052
amphetamine sensitization effects on, 743
attention-deficit/hyperactivity disorder-related deficits of, 439, 1256
deficits of, 439, 1256
dehydration effects on, 422
executive function, 761
heat effects on, 422
major depression-related deficits in, 1089
sleep loss effects on, 422
smoking affected by, 56
undernutrition effects on, 422
Cognitive behavioral therapy, for binge eating disorder
description of, 301
with orlistat, 1193
Cognitive function decrement
in schizophrenia, 688
Conduct disorder
abnormal neural responses in, 7
adolescents with, 7, 1109
Conflict processing
alcoholism affected by, 67
Cortex
transcranial magnetic stimulation effects on, 752
Corticolimbic blood flow
in posttraumatic stress disorder, 832
Corticosteroids
declarative memory affected by, 543
mood affected by, 543
Corticotropin-releasing hormone
acoustic startle reactivity and, 85
associative learning changes and, 85
behavioral inhibition and, 1485
Cortisol hypersecretion
depression and bone mineral density, correlation between, 911
stress-induced, 911
Criminal psychopaths
prefrontal cortex volume reduction in, 1103
[11C]WAY-100635
5-HT1A receptor binding in chronic fatigue syndrome measured using, 239

Dab 1, 777
D-amino-acid oxidase
in schizophrenia, 1493
D-cycloserine
learned fear extinction by, 841
Declarative memory
corticosteroid therapy effects on, 543
phenytoin effects on, 543
Deep brain stimulation
obsessive-compulsive disorder treated with, 510
Dehydration
cognition affected by, 422
Delta-9-tetrahydrocannabinol
in schizophrenia, 594
Depression. *See also* Major depression
adolescents with, 1477
in Alzheimer's disease, 412
amitriptyline for, 162
anhedonic phenotype in, 319
bone mineral density and, 911
brain-derived neurotrophic factor levels in, 1068
cell adhesion molecule L1 alterations in, 716
dorsolateral prefrontal cortex in, maternal criticism and praise effects on, 809
families at risk for, 953
functional magnetic resonance imaging of, 1079
limbic activation in, 1079
long-term, 113
mood regulating circuit in, 1079
regional cerebral metabolism in, 220

risks for, 953
suicidal behavior in, hypothalamus-pituitary-adrenal system regulation of, 336
Diffusion tensor imaging
attention-deficit/hyperactivity disorder studied using, 448
Dissociation
in posttraumatic stress disorder, 873
Disulfiram
alcoholism treated with, 1128
Diurnal cortisol rhythm, 373
Dopamine
fetal alcoholic syndrome and, 1565
methylphenidate effects on, 1410
Dopamine D2 receptor binding
in adolescents with attention-deficit/hyperactivity disorder, 229
Dopamine D4 receptor gene 48-base-pair repeat polymorphism, 999
Dopamine transporters
in attention-deficit/hyperactivity disorder, 229, 1293, 1397
radafaxine effects on, 640
Dopaminergic neurons
of ventral midbrain, methylphenidate effects on, 361
Dorsal raphe nucleus
frontocortical 5-HT4 receptors effect on, 918
tryptophan hydroxylase-1 expression in, estrogen receptor-β regulation of, 938
tryptophan hydroxylase-2 mRNA hormonal regulation in, 943
Dorsolateral prefrontal cortex
dysfunctional, 809
maternal criticism and praise effects on, 809
D-serine
risperidone and olanzapine with, 577
schizophrenia treated with, 577
*DTNBP1* polymorphisms
bipolar disorder and, 696
Dysbindin polymorphisms
bipolar disorder and, 696
Dyslexia, 1301

Electroconvulsive shock
Cdk2-pRB-E2F1 cell cycle pathway activation by, 107
Electroencephalography
regional hemispheric activity in offspring at risk for major depression measured using, 328
Emergency department heart rate
posttraumatic stress disorder and, 91
Emotional reactivity
rimonabant effects on, in rodents, 261
Emotions
amygdala's role in, 624
in major depression, 1089
striatum's role in, 624
Estrogen receptor-β
tryptophan hydroxylase-1 expression in murine midbrain raphe mediated by, 938
Euthymic bipolar disorder, 183
Executive cognitive function
in mild cognitive impairment, 761

Facial expressions
in major depression, 201
neural response to, 201
Fear
amygdala response during, 1517
extinction of, 1559
Fear conditioning
sleep disturbances in posttraumatic stress disorder affected by, 268
Fear inhibition, 1559
Fear potentiation, 1559
Fear-potentiated startle
anxiogenic treatments effect on, 33
in mice, 33
Fetal alcoholic syndrome
deep serotonergic structures in, 1565
dopaminergic structures in, 1565
magnetic resonance imaging volumetry of, 1565
Fetal irradiation
gray matter affected by, 83
white matter affected by, 83
Fluoxetine
binge eating disorder treated with, 301
major depression treated with, 1535
Forebrain nuclei volume
in alcoholism, 768
Fos-immunoreactive cholinergic neurons, 1138
Frontal cortex
localized enlargement of, in early autism, 126
Frontocortical 5-HT4 receptors, 918
Fronto-thalamo-strial gray volume
in bipolar disorder, 733
[18F]Setoperone, 1004
Functional magnetic resonance imaging
depression, 1079
dyslexia, 1301
event-related, for executive control in mild cognitive impairment, 761
hemispheric specialization for language in schizophrenia, 1020
obsessive-compulsive disorder studied using, 901
posterior cingulate cortex activation reductions in alexithymia subjects, 982
posttraumatic stress disorder dissociative responses studied using, 873
schizophrenia evaluations, 726
transcranial magnetic stimulation and, 752

GABA-A receptor subunit mRNA, 49
t-Aminobutyric acid
cortical, 44
description of, 1583
in menstrual cycle, 44
nicotine and, 44
smoking on, 44
Genetics
of attention-deficit/hyperactivity disorder, 647, 1215, 1285, 1310, 1313
Ghrelin, 926
Glutamate receptors
in long-term potentiation, 113
Glycogen synthase kinase-3
hypoxia activation of, 278
imipramine effects on, 278
mood stabilizers effect on, 278

Gray matter
fetal irradiation on, 83
prefrontal volume reduction, in criminal psychopaths, 1103
GSK-3
antipsychotics' effect on protein expression levels of, 533

Haplotype mapping, of attention-deficit/hyperactivity disorder, 1357
Heat stress
cognition affected by, 422
Hemispheric specialization for language
in schizophrenia, 1020
Hemodynamics
in schizophrenia, during auditory oddball task, 1029
Heschl's gyrus
in schizophrenia, 947
Hippocampus
activation of, in response to fearful faces in schizophrenia, 1011
in borderline personality disorder, 173
neural cell adhesion molecule expression decreased in, 856
in posttraumatic stress disorder, 173
in schizophrenia, 633, 702
ventral, neonatal lesions of, 49
volume of, in major depression, 21, 935
HIV
alcoholism and, 67
Hormones
antisocial behavior and, 10109
5-HT1A, 559
5-HT1A receptor binding
in chronic fatigue syndrome, 239
positron emission tomography of, 239
5-HT1D
in obsessive-compulsive disorder, 1176
5-HT1B, 559
5-HT2 receptors
electroconvulsive shock effects on binding to, 1004
5-HT2C
in obsessive-compulsive disorder, 1176
5-HT4
agonists of, 918
receptors, 918
5-HTTLPR serotonin transporter
in amygdala response to threatening stimuli, 1517
in major depression, 247
Huntington's disease, 1583
Hypercortisolemia, 155
Hyperhomocysteinemia, alcoholism-associated, 1590
Hypothalamus-pituitary-adrenal system
adverse rearing effects on, 373
maternal separation effects on, in monkeys, 373
regulation of, 336
suicidal behavior in depression regulated by, 336
Hypoxia
glycogen synthase kinase-3 activated by, 278

Imipramine
glycogen synthase kinase-3 serine-dephosphorylation blocked by, 278
Impulsivity
yohimbine effects on, 1209
Infants
maternal maltreatment effects on, 823
Insular cortex
schizophrenia and, 394
Interleukin-12
in Tourette's syndrome, 667
Ischemic stroke
anxious phenotype after, 1166
hyperactive phenotype after, 1166

Kappa opioid receptors
prepulse inhibition of startle disrupted by, 1550
Ketamine
distractibility induced by, 366

Language
hemispheric specialization for, in schizophrenia, 1020
*LARS2*, 525
Learned fear
D-cycloserine effects on, 841
extinction of, 841
Learning
associative, corticotropin-releasing hormone effects on, 85
Lithium
riluzole and, for bipolar depression, 430
Locomotor hyperactivity
blockade of, induced by prefrontal cortex α2-adrenergic receptors, 192
Long-term depression, 113
Long-term plasticity
postsynaptic signaling networks and, 113
Low-field magnetic stimulation
antidepressant-like effects of, 571

Magnetic resonance spectroscopy, 44
Major depression. *See also* Depression
attention deficit in, 183
cell adhesion molecule L1 alterations in, 716
cognitive deficits in, 1089
emotional stimuli in, 1089
facial expressions in, 201
fluoxetine for, 1535
hippocampus volumes in, 21, 935
5-HTTLPR serotonin transporter polymorphism and, 247
*myo*-inositol in prefrontal cortex in, 1526
neurochemical markers for, 252
norepinephrine reuptake inhibitors for, 1535
offspring at risk for, 328
pediatric
amygdala volumes in, 21
hippocampus volumes in, 21
reboxetine for, 1535
regional hemispheric activity in, electroencephalographic measures of, 328
sad expressions in, 201
selective serotonin reuptake inhibitors for, 1535
Maternal maltreatment
memory of, 823
neonatal behavioral correlates of, 823
Maternal separation
anxiety disorders and, 373
hypothalamus-pituitary-adrenal system effects, 373

Mecamylamine
smoking cue reactivity in schizophrenia affected by, 802
Medial temporal lobe
functional disconnectivity of, in Asperger's syndrome, 991
Melatonin
production of, in autism, 134
Memory
phenytoin effects on, 543
spatial, stress-induced impairment of, 856
Menstrual cycle
t-aminobutyric acid in, 44
Methamphetamine
attentional control affected by, 310
brain abnormalities in, 967
selective attention affected by, 310
striatum enlargements in, 967
Methionine
schizophrenia-like epigenetic behavioral modifications induced by, 500
Methylphenidate
attention-deficit/hyperactivity disorder treated with, 1410, 1477
cocaine-induced potentiation reduced by, 120
dopamine affected by, 1410
dopaminergic neurons of ventral midbrain affected by, 361
early developmental exposure to, 120
rat studies of, 120
Mifepristone
schizophrenia affected by, 155
Mild cognitive impairment. *See also* Cognition
Alzheimer's disease and, 761
event-related functional magnetic resonance imaging studies of, 761
executive cognitive function in, 761
Mitochondrial DNA 3243A >G mutation
in bipolar disorder, 525
in schizophrenia, 525
Mitogen-activated protein kinase signal transduction pathway
clozapine's antipsychotic actions affected by, 617
Monkeys
acoustic startle response in, 373
ketamine-induced distractibility in, 366
Monoamine oxidase A gene
aggressive behavior and, 167
Mood
corticosteroid therapy effects on, 543
phenytoin effects on, 543
Mood disorders
dopamine D4 receptor gene 48-base-pair repeat polymorphism and, 999
Mood stabilizers
glycogen synthase kinase-3 serine-dephosphorylation blocked by, 278
*Myo*-inositol, 1526

Naltrexone
alcoholism treated with, 1128
Negative affect
voluntary suppression of, 210
Neonates
maternal maltreatment correlates for, 823
Netrin-G1, 382
Netrin-G2, 382
Neural cell adhesion molecules
in hippocampus, 856
in prefrontal cortex, 856
Neurobehavior disinhibition, 76
Neurocognitive function
in schizophrenia, mifepristone effects on, 155
Neuroinflammation
peroxisome proliferator-activated receptor gamma activation effects on, 885
Neuronal protein, 1479
Neuroreceptor imaging
in attention-deficit/hyperactivity disorder, 1293
Nicotine
behavioral sensitization and, 351
rapid delivery of, 351
t-aminobutyric acid and, 44
N-methyl-D-aspartate receptor
blockade, schizophrenia-related cognitive deficits caused by, 433
D-serine levels and, 1493
prepulse inhibition of startle affected by, 1147
in schizophrenia, 1493
Nonpsychotic bipolar disorder, 633
Norepinephrine
cocaine's behavioral effects affected by, 1202
Norepinephrine reuptake inhibitors
for major depression, 1535

Obsessive-compulsive disorder
animal model of, 1176
anterior cingulate in, error-related hyperactivity of, 287
brain activation of patients with, 901
early-onset, 895
familial, 895
functional magnetic resonance imaging study of, 901
5-HT1D receptors in, 1176
5-HT2C receptors in, 1176
neuropsychological provocation tasks for, 901
prepulse inhibition of acoustic startle impairments in, 1153
refractory, deep brain stimulation for, 510
sensory gating mechanisms in, hypofunctioning of, 16
somatosensory evoked potentials in, 16
sporadic, 895
Sydenham chorea and, 1073
symptom provocation tasks for, 901
Olanzapine
D-serine and risperidone with, 577
schizophrenia treated with, 577
vacuous chewing movements in rats induced by, 406
Olfactory bulbectomized rats
microdialysis study of, 1061
serotonergic functioning of, 1061
Omega-3 fatty acids
antidepressant-like effects of, 343
Orlistat and cognitive behavioral therapy
binge eating disorder treated with, 1193

P300
in childhood use disorders, 76
neurobehavior disinhibition and, 76
in substance use disorders, 76
P50 suppression
in schizophrenia, 1504

Panic disorder
in children, 1485
Parietal cortex
in borderline personality disorder, 173
Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, 788
Penicillin
streptococcal infection prophylaxis using, 788
Peptide YY, 926
Perceptual load
alcoholism affected by, 67
Peroxisome proliferator-activated receptor gamma
activation of, 885
neuroinflammation in brain after stress decreased by, 885
Personality
temperament dimensions in, 1
Platelet reactivity
brain-derived neurotrophic factor and, 1068
Positron emission tomography
with [11C]DASB, 1510
5-HT1A receptor binding in chronic fatigue syndrome measured using, 239
serotonin transporter availability in schizophrenia studied using, 1510
Posterior cingulate cortex
alexithymia and, 982
Postmortem diagnosis, 96
Postsynaptic signaling networks
long-term plasticity and, 113
Posttraumatic stress disorder
amygdala activity in, 464
childhood sexual abuse-related, in women, 1186
combat-related, 474
corticolimbic blood flow in, during script-driven imagery, 832
dissociative responses in, 873
emergency department heart rate and, 91
functional magnetic resonance imaging of, 873
hippocampal size in, 173
risperidone for, 474
sleep disturbances in, rodent model of, 268
PPP3CC, 702
Prazosin, 1202
Prefrontal cortex
α2-adrenergic receptors, locomotor hyperactivity induced blockade of, 192
aging effects on, 549
catecholamine influences on, 1377
CB1 receptor-mediated G-protein signaling in, 480
dopamine turnover reductions in, secondary to amphetamine sensitization, 743
dorsolateral, maternal criticism and praise effects on, 809
early life stress effects on, 848
endocannabinoids in, 480
medial, 918
*myo*-inositol, in major depressive disorder, 1526
neural cell adhesion molecule expression decreased in, 856
reflexive saccade inhibition, 1159
saccadic eye movements affected by, 1159
social isolation rearing effects on, 1205
volume reduction of, in criminal psychopaths, 1103
Prepulse inhibition of startle
impaired, in obsessive-compulsive disorder, 1153
kappa opioid receptor activation disruption of, 1550
N-methyl-D-aspartate receptor NR3A subunit effects on, 1147
Presynaptic protein mRNA, 1041
Preterm birth
in adolescents, hyperactivity associated with decreased caudate volume, 661
Primary motor cortex
transcranial magnetic stimulation effects on, 752
Protein function analysis, 1479
Proton magnetic resonance spectroscopy, 44
Psychopaths
prefrontal cortex volume reduction in, 1103
Psychosis
cannabinoids and, 594
cannabis and, 1117
first-episode, 947
Psychotic bipolar disorder, 633
Pyramidal neurons
in an inducible knockout of brain-derived neurotrophic factor, 932

Radafaxine
dopamine transporter blockade by, 640
Raphe nuclei
description of, 559
dorsal
frontocortical 5-HT4 receptors effect on, 918
tryptophan hydroxylase-1 expression in, estrogen receptor-β regulation of, 938
tryptophan hydroxylase-2 mRNA hormonal regulation in, 943
Rats
attention-deficit/hyperactivity disorder models, 1239
low-field magnetic stimulation effects as antidepressant in, 571
methylphenidate studies in, 120
olfactory bulbectomized, serotonergic functioning of, 1061
stimulant actions in, 1391
vacuous chewing movements in, olanzapine infusion effects on, 406
Rearing
hypothalamus-pituitary-adrenal system affected by, 373
Reboxetine
major depression treated with, 1535
Reelin signaling
in autism, 777
Regional cerebral metabolism
in Alzheimer's disease, 412
in depression, 220
Response inhibition, 1285
Riluzole
lithium and, for bipolar depression, 430
Rimonabant
emotional reactivity in rodents affected by, 261
Risk perception, 1477
Risperidone
D-serine and olanzapine with, 577
posttraumatic stress disorder treated with, 474
schizophrenia treated with, 577

Saccadic eye movements
in Alzheimer's disease, 1052
prefrontal dysfunction effects on, 1159

Sad expressions
in major depression, 201
Schizophrenia
amphetamine sensitization and, 586
animal model of, 586
apolipoprotein E in, 711
attentional dysfunctions of, 1138
auditory hallucinations in, transcranial magnetic stimulation effects on, 188
calcineurin expression in, 702
calcium-independent phospholipase A2 activity in, 399
catechol-O-methyltransferase gene Val/Met polymorphism and, 139
celecoxib augmentation for, 1594
cognitive deficits in
delta-9-tetrahydrocannabinol effects, 594
description of, 145
N-methyl-D-aspartate receptor blockade and, 433
cognitive function decrement in, 688
consent to treatment for, 609
corticofugal dysregulation in, 145
D-amino-acid oxidase in, 1493
delta-9-tetrahydrocannabinol effects, 594
D-serine for, 577
epigenetic behavioral modifications in, valproate for, 500
fearful faces in, hippocampal responses to, 1011
first-episode
calcium-independent phospholipase A2 activity in, 399
neuropsychological basis of competence to consent to treatment in, 609
functional magnetic resonance imaging study of, 726
gamma-aminobutyric acid-ergic function in, 49
hemispheric specialization for language in, 1020
hemodynamics in, during auditory oddball task, 1029
Heschl's gyrus dysfunction in, 947
hippocampus
decreased expression of, 702
volume of, 633
hypercortisolemia effects on, 155
insular cortex abnormalities in, 394
ketamine as pharmacological model of, 366
*LARS2* gene expression in, 525
metacognition effects, 609
mifepristone effects on neurocognitive function and symptoms in, 155
mitochondrial DNA 3243A >G mutation expression in, 525
netrin-G1 and -G2 expression in, 382
neurochemical markers for, 252
neuropathology of, 83
n-methyl-D-aspartate receptor neurotransmission in, 1493
olanzapine for, 577
P50 suppression in, 1504
positron emission tomography of, 1510
postmortem diagnosis of, 96
PPP3CC gene expression in, 702
prepulse inhibition deficits in, 817
"prodromal" state of, 586
psychiatric diagnosis of, 96
risperidone and olanzapine with D-serine for, 577
serine racemase mRNA isoforms in, 1493
serotonin transporter in, 1510
smoking cue reactivity in, mecamylamine effects on, 802
smooth pursuit eye movements in, 726
unreality symptoms in, 947
ventricular volumes in, 633
visually guided saccades abnormalities in, 145
in women, 817
Selective attention
methamphetamine effects on, 310
Selective serotonin reuptake inhibitors
fluoxetine, 301, 1535
major depression treated with, 1535
Sensory gating mechanisms
hypofunctioning of, in obsessive-compulsive disorder, 16
Serine racemase mRNA isoforms
in schizophrenia, 1493
Serotonin
frontocortical 5-HT4 receptors effect on, 918
physical activity effects on, 559
stress and, 295
tryptophan depletion effects on, 517
Serotonin transporter
5-HTTLPR
in amygdala response to threatening stimuli, 1517
in major depression, 247
physical activity effects on, 559
in schizophrenia, 1510
tryptophan depletion on [11C]-DASB binding to, 102
wheel running effects on, in rats, 559
Sexual abuse, childhood
posttraumatic stress disorder caused by, in women, 1186
Short interval intracortical inhibition, 1597
Single photon emission computed tomography
attention-deficit/hyperactivity disorder studies using, 1273
nor-β-CIT, 1565
Sleep disturbances
cognition affected by, 422
fear conditioning effects on, 268
in posttraumatic stress disorder, 268
Smoking
abstinence of, 56
in adolescents, 56
cognition affected by, 56
t-aminobutyric acid levels affected by, 44
Smoking cue reactivity
mecamylamine effects on, in schizophrenia, 802
Smooth pursuit eye movements
in schizophrenia, 726
Social isolation rearing
prefrontal cortex response to ventral tegmental area stimulation affected by, 1205
Social phobia
anterior cingulate cortex in, 975
Solute carrier family 1-member 3 gene, 1461
Somatosensory evoked potentials
in obsessive-compulsive disorder, 16
Spatial memory
stress-induced impairment of, 856
Startle
acoustic. *see* Acoustic startle
fear-potentiated
anxiogenic treatments effect on, 33
in mice, 33
Stimulants, for attention-deficit/hyperactivity disorder, 1391
Streptococcal infections, 788

Stress
anxious state induced by, 865
brain activation and, 487
brain neuroinflammation induced by, 885
childhood trauma and, 27
cocaine use and, 487
cortisol hypersecretion in response to, 911
serotonin and, 295
tryptophan depletion effects on response to, 295
Stress hormones
antisocial behavior and, 10109
Striatum
emotion regulation and, 624
gamma-aminobutyric acid transmission in, 1583
of Huntington's disease mice, 1583
in methamphetamine abusers, 967
Stroop Match-to-Sample Task, 67
Substance abuse
stimulants for, 1391
Substance use disorders
P300 amplitude in, 76
Suicidal behavior
in depression, 336
hypothalamus-pituitary-adrenal system regulation of, 336
Suicide
endocannabinoid levels in, 480
6-Sulphatoxymelatonin
nocturnal excretion of, in children and adolescents with autism, 134
Sydenham chorea
obsessive-compulsive disorder symptoms in, 1073
Systemic lupus erythematosus
behavioral heterogeneity in, 679
neuropsychiatric, 679

Temperament
in personality, 1
Threatening stimuli
amygdala response during, 1517
Thyroid hormone alterations
in women with posttraumatic stress disorder secondary to childhood sexual abuse, 1186
Topiramate
borderline personality disorder-related aggression treated with, 495
Tourette's syndrome
attention-deficit hyperactivity disorder and, 1597
interleukin-12 levels in, 667
short interval intracortical inhibition and, 1597
tumor necrosis factor-alpha levels in, 667
Transcranial magnetic stimulation
amitriptyline effects accelerated by, 162
antidepressant-like effects of, 571
cortical brain effects of, 752
schizophrenia-related auditory hallucinations reduced using, 188
subcortical brain effects of, 752
Tryptophan
depletion of
[11C]-DASB binding to serotonin transporter and, 102
depressive symptoms and, 517
stress responses affected by, 295
plasma levels of, during weight restoration in anorexia nervosa patients, 674
Tryptophan hydroxylase-1
estrogen receptor-β regulation of, 938
Tryptophan hydroxylase-2 mRNA, 943
Tumor necrosis factor-alpha
in Tourette's syndrome, 667

Unconscious emotional responses
temperament dimensions in, 1
Undernutrition
cognition affected by, 422
Uridine
antidepressant-like effects of, 343

Vacuous chewing movements
olanzapine infusion inducement of, in rats, 406
Valproate
schizophrenia-like epigenetic behavioral modifications corrected using, 500
Venlafaxine
regional cerebral metabolism and, 220
Ventral hippocampus
GABA-A receptor subunit mRNA expression in, 49
neonatal lesions of, 49
Ventral midbrain
dopaminergic neurons of, methylphenidate effects on, 361
Ventral tegmental area stimulation
social isolation rearing effects on, 1205
Ventricles
in schizophrenia, 633
Verbal memory
impairments of, 56

White matter
fetal irradiation on, 83
volume of, in bipolar disorder, 733
Women
childhood sexual abuse in. posttraumatic stress disorder secondary to, 1186
parietal cortex of, in borderline personality disorder, 173
Working memory
in attention-deficit/hyperactivity disorder, 439
deficits of, in alcoholism, 768
impairments of, 56

Yohimbine
impulsivity increased by, 1209